1 Recent SARS-CoV-2 seroconversion in a national, community-based

2

prospective cohort of U.S. adults

| 3 | Authors: Denis Nash ^{1,2*} , Madhura Rane ¹ , Mindy Chang ¹ , Sarah Gorrell Kulkarni ¹ , Rebecca |
|---|--|
| 4 | Zimba ¹ , William You ¹ , Amanda Berry ¹ , Chloe Mirzayi ^{1,2} , Shivani Kochhar ¹ , Andrew Maroko ^{1,3} , |
| 5 | McKaylee M. Robertson ¹ , Drew Westmoreland ¹ , Angela Parcesepe ^{1,4,5} , Levi Waldron ^{1,2} , and |
| 6 | Christian Grov ^{1,6} |

7 Affiliations:

| 8 9 | ¹ Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); New York City, New York USA |
|----------------|---|
| 10 11 | ² Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York |
| 12 | USA |
| 13 14 15 | ³ Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA |
| 16 17 | ⁴ Department of Maternal and Child Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA |
| 18 19 | ⁵ Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA |
| 20 21 22 | ⁶ Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA |
| 23 24 | *CORRESPONDING AUTHOR: |
| 24 25 | Denis Nash, Ph.D., MPH |
| 26 | City University of New York (CUNY) Graduate School of Public Health and Health Policy |
| 27 | 55 W. 125th St., 6th Floor |
| 28 | New York, NY USA 10027 |
| 29 | Email: <u>denis.nash@sph.cuny.edu</u> |
| 30 | Twitter: @epi_dude |

31 SHORT ABSTRACT

- 32 Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via
- 33 prospective cohort studies, complementing case-based surveillance and cross-sectional
- 34 seroprevalence studies. In March 2020, we launched the CHASING COVID Cohort Study, a
- national, community-based prospective cohort study of 6,745 U.S. adults who underwent at-
- 36 home specimen collection for repeat serologic testing for SARS-CoV-2 antibodies. We identify
- and quantify several policy-sensitive risk factors for recent SARS-CoV-2 seroconversion,
- 38 highlight persistent racial/ethnic disparities in incidence, document continued elevated risk
- among essential workers, and call attention to major gaps in the coverage of public health
- 40 interventions aimed at testing, isolation, and contact tracing. We conclude that modifiable risk
- 41 factors and poor reach of public health strategies drive SARS-CoV-2 transmission and inequities
- 42 across the U.S.

43

44 LONG ABSTRACT

45 Background

46 Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via

- 47 prospective cohort studies, complementing case-based surveillance and cross-sectional
- 48 seroprevalence studies.
- 49

50 Methods

- 51 We estimated the cumulative incidence of SARS-CoV-2 infection and incidence rates of
- 52 seroconversion in a national prospective online cohort of 6,745 U.S. adults, enrolled March-July
- 53 2020. A subset (n=4,459) underwent serologic testing (Bio-Rad Platelia Total Ab,
- ⁵⁴ IgA/IgM/IgG), offered initially May-September 2020 and again November 2020-January 2021.
- 55

56 **Results**

- 57 A total of 303 of 4,459 individuals showed serologic evidence of past SARS-CoV-2 infection
- 58 (cumulative incidence of 6.8%; 95% Confidence Interval [CI] 6.1%-7.6% [6.3%, 95% CI 5.7%-
- 59 7.1% adjusting for laboratory test error]). Among 3,280 initially seronegative participants with a
- subsequent serologic test, we observed 145 seroconversions during 1,562 person years of follow-
- ⁶¹ up (incidence rate of 9.3 per 100 person-years [95% CI 17.9-11.0]). Racial/ethnic disparities in
- 62 crude incidence rates were apparent through January 2021 (rate ratio [RR_{Hispanic vs Whites}]=2.1;
- 63 95% CI 1.4-3.1; RR_{non-Hispanic Blacks vs Whites}=1.8; 95% CI 0.96-3.1). Incidence was higher in the
- 64 southern (RR_{South vs Northeast}=1.7; 95% CI 1.1-2.8) and midwestern (RR_{Midwest vs Northeast}=1.6; 95%
- 65 CI 0.98-2.7) regions, in rural vs urban areas (RR=1.5; 95% CI 1.0-2.2), and among essential
- 66 workers (RR=1.7; 95% CI 1.1-2.5). Household crowding (RR=1.6, 95% CI 1.1-2.3), dining
- 67 indoors at restaurants/bars (RR=2.0; 95% CI 1.4-2.8), visiting places of worship (RR=2.0; 95%
- 68 CI 1.3-2.9), wearing masks sometimes vs always while grocery shopping (RR=2.5; 95% CI 1.3-
- 69 4.4), indoor visits with people outside the household with masks ($RR_{always mask vs no visit}=2.6$; 95%
- 70 CI 1.6-4.4) and without masks (RR_{sometimes mask vs no visit}=3.5; 95% CI 2.7-5.7; RR_{never mask vs no}
- 71 visit=5.3; 95% CI 3.1-8.9); working indoors at a place of employment with masks (RR_{always mask vs}
- 72 no in-person=2.0, 95% CI 1.4-2.8) and without masks (RR_{sometimes mask vs no in-person}= 2.0, 95% CI 1.1-

- 73 3.5; RR_{never mask vs no in-person}=3.7, 95% CI 1.3-8.5); attending a salon or gym with masks (RR_{always}
- $_{\text{mask vs no salon/gym}}=1.7 (95\% \text{ CI } 1.1-2.4)$, gathering indoors and outdoors in groups of $\geq 10 (\text{RR}=1.9, \text{M})$
- 75 95% CI 1.2-2.0); and air travel during the pandemic (RR=1.7; 95% CI 1.1-2.6) were also
- associated with higher incidence rates. Among 303 seropositive individuals, 27.4% had
- asymptomatic infection, and 32% reported a positive SARS-CoV-2 PCR test or provider
- diagnosis of COVID-19. In this group, there were major gaps in the coverage of public health
- ⁷⁹ interventions aimed at isolation (31% isolated) and contact tracing (asked about contacts [18%];
- told about exposure to a confirmed case [7.6%]).
- 81

82 Conclusions

- 83 Modifiable risk factors and low reach of public health strategies drive SARS-CoV-2 transmission
- across the U.S. It is critical to address inequities in incidence, reduce risk factors, and improve
- the reach of public health strategies in the vaccine era.
- 86
- 87 **KEYWORDS:** COVID-19; serology, seroconversion, asymptomatic infection, physical
- distancing; natural history study, epidemiologic study, essential workers, public health
- 89 interventions, community transmission
- 90 91

92 INTRODUCTION

As of this writing, about one year after the emergence of SARS-CoV-2 in the United States

- 94 (U.S.), there have been more than 25 million SARS-CoV-2 cases diagnosed, 435,000 deaths
- ⁹⁵ recorded, and 23.5 million vaccine doses administered.¹ As compared to *diagnoses*, the true

number of *infections* to date in the U.S. is unknown, but national estimates in the general

97 population as measured by seroprevalence have put the cumulative incidence at 10% in

98 September 2020^2 and 14% as of November 2020.³ One recent study in a nationally

99 representative sample of U.S. adults found that 4.6% had a history of undiagnosed SARS-CoV-2

100 as of July 2020: about 5 undiagnosed infections for every diagnosed case.⁴

101 A major challenge of controlling community transmission of SARS-CoV-2 is that the virus' 102 infectious period allows for onward spread prior to recognition of infection, by the substantial 103 proportion of people with asymptomatic infection, and during the pre-symptomatic period among 104 those who go on to develop symptoms.^{4,5}

While SARS-CoV-2 is understood to be transmitted from person-to-person via droplet and 105 airborne spread, to date, the incidence of SARS-CoV-2 infection and risk factors for incident 106 infection have not been well-characterized by routine case-based surveillance of SARS-CoV-2 107 diagnoses or by cross-sectional seroprevalence studies.^{1–3} As the pandemic progresses through 108 different seasons and stages, it is critical to continue to characterize COVID-19's evolving 109 epidemiology and risk factors for SARS-CoV-2 acquisition, the uptake and impact of non-110 pharmaceutical interventions $(NPIs)^6$, and the reach of public health strategies aimed at 111 controlling community transmission, including testing, quarantine, isolation, contact tracing, and 112 vaccination. 113

Researchers and public health practitioners have called for prospective cohort studies to 114 115 describe incidence rates and how they are influenced by NPI implementation and uptake, sociodemographics, knowledge and behaviors, and other potential risk factors.⁷ Yet, both the 116 frequency with which many risk factors occur in community samples, as well as the SARS-CoV-117 2 risk that could be attached to them, still have not been systematically assessed and 118 119 epidemiologically linked to outcomes like seroconversion. Globally, few prospective epidemiologic studies of SARS-CoV-2 have been published to date. One recent global 120 systematic review of observational studies of SARS-CoV-2 that employed serologic or PCR 121 testing found 18 prospective studies.⁸ Most were focused on healthcare workers or other 122

123 occupational groups, individuals in congregate settings, evacuees, or cruise ships; none were

- 124 community-based (i.e., focused on risk factors in communities vs other higher risk
- 125 populations/settings).⁸ A greater understanding of SARS-CoV-2 incidence and risk factors in
- 126 community samples can substantially complement routine case-based surveillance of new SARS-
- 127 CoV-2 diagnoses and cross-sectional serosurveys, serving to inform aspects of implementation
- 128 of the public health response and policies.

In late March 2020, we launched the national, prospective Communities, Households and

- 130 SARS-CoV-2 Epidemiology (CHASING) COVID Cohort.⁹ We describe the cumulative
- 131 incidence of SARS-CoV-2 infection, risk factors for recent SARS-CoV-2 seroconversion, and,
- 132 for those with serologic evidence of prior SARS-CoV-2 infection, the reach and uptake of public
- 133 health strategies.
- 134

135 **METHODS**

- We used internet-based strategies 10-12 to recruit a geographically and socio-demographically
- diverse cohort of adults in the U.S. and U.S. territories into longitudinal follow-up with at-home
- specimen collection. To be eligible for inclusion in the cohort, individuals had to: 1) reside in the
- U.S. or a U.S. territory; 2) be aged 18 years or older; 3) provide a valid email address for follow-
- up; and 4) demonstrate early engagement in study activities (provided a baseline specimen or
- 141 completed >1 recruitment/enrollment visits). Details of the study design and recruitment
- 142 procedures have been described previously.⁹
- 143

144 Study measurements

Participant interviews. Measures included on the cohort screening, enrollment and follow-up 145 questionnaires were derived from published research¹⁰, BRFSS¹³, 2009 H1N1 influenza 146 studies^{14,15}, and other COVID-19 studies.¹⁶ Measures were also developed *de novo*. Cohort 147 recruitment and enrollment visits were completed between March 28-August 21, 2020, during 148 which multiple rounds of interviews took place. Essential worker status was defined as working 149 150 in law enforcement, emergency management, delivery, transportation, construction or healthcare at study enrollment. We separated healthcare workers from other essential workers and treated 151 them as distinct categories in our analyses. From follow-up interviews we obtained repeated 152

measurements of symptoms, testing, hospitalizations, quarantine, isolation, contact tracingencounters, and other time-varying factors.

At-home specimen collection for serologic testing. As part of study assessments during 155 May-August 2020 (Period 1) and November 2020-January 2021 (Period 2), participants were 156 invited to participate in serologic testing using an at-home self-collected dried blood spot (DBS) 157 specimen collection kit. Consenting participants were mailed a specimen collection kit, which 158 included written instructions and a QR code for an instructional video. DBS cards were sent from 159 and returned to the study laboratory (Molecular Testing Laboratories [MTL], Vancouver, 160 Washington) via the U.S. Postal Service (self-addressed, stamped envelope containing a 161 biohazard bagTM). 162

Serologic testing. All DBS specimens were tested by the study laboratory for total 163 antibodies (Total Ab) using the Bio-Rad Platelia test for IgA, IgM, and IgG which targets the 164 SARS-CoV-2 nucleocapsid protein (manufacturer sensitivity 98.0%, specificity 99.3%).¹⁷ 165 Specimens that were reactive on the Total Ab test were tested further using the Euroimmun IgG 166 test which targets the SARS-CoV-2 spike protein (manufacturer sensitivity 100%; specificity 167 99%).¹⁷ Both assays received Emergency Use Authorization from the U.S. Food and Drug 168 Administration and were further validated for use with DBS by the study laboratory using 169 170 confirmed, true positive and negative patient specimens. In these local validations, both assays were found to have 100% sensitivity and 100% specificity (MTL, personal communication). 171 172 Cumulative incidence of SARS-CoV-2 infection. Among participants who underwent serologic testing, we estimated the cumulative incidence of SARS-CoV-2 as the proportion of 173 individuals with a positive Total Ab test in either of the two time periods (i.e., number of 174 participants ever-positive) divided by the total number of persons with one or more Total Ab 175 176 tests (i.e., number of participants ever tested). We adjusted cumulative incidence estimates for laboratory test error as reported by the kit manufacturer. Crude cumulative incidence estimates 177 are presented alongside adjusted estimates in supplemental tables. Unless otherwise specified, all 178 cumulative incidence estimates presented are adjusted for laboratory test error using the 179 following formula¹⁸: 180

 $\label{eq:adjusted} \textit{Adjusted cumulative incidence} = \frac{\textit{Crude cumulative incidence} + \textit{Specificity} - 1}{\textit{Sensitivity} + \textit{Specificity} - 1}$

181

Observed SARS-CoV-2 seroconversion and seroreversion. Among those individuals with 182 two Total Ab tests, an observed seroconversion was defined as a negative Total Ab test in Period 183 184 1 followed by a positive Total Ab test in Period 2. We estimated the rate of seroconversion per 100 person years of follow-up using the collection dates for each specimen. Person-time at risk 185 began at the time of dried blood spot sample collection for the first serologic test or date the lab 186 received the sample if collection date was missing. The seroconversion date was assigned as the 187 midpoint between the first and second sample collection dates. Observed seroreversion was 188 defined as a positive Total Ab test in Period 1 followed by a negative Total Ab test in Period 2. 189 190

191 Statistical analysis

192 Cumulative incidence estimates and 95% confidence intervals (95% CIs) were stratified by

193 enrollment characteristics and risk factors acertained prior to specimen collection. Incidence

194 proportions (observed seroconversions) were also stratified by risk factors measured prior to the

date of specimen collection in Period 2. All data were cleaned and analyzed in R (version 4.0.3)

and SAS (V9.4). Data were geocoded based on a self-reported ZIP code, and maps were created

in ArcGIS 10.7. For categorical variables with missing data frequency <5%, we imputed missing

198 data for participants using the most common value among all participants for a given variable.

199

200 Ethical Approval

The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY) Graduate School for Public Health and Health Policy.

203

204 **RESULTS**

205 The characteristics of the cohort are shown in Table 1, which includes participants from all 50

U.S. states, the District of Columbia, Puerto Rico, and Guam (see Fig. S1). Of the 6,745

207 participants enrolled in the cohort, 4,459 (66%) had at least one serologic test (Table 1).

208 Compared with the entire cohort, those who underwent any serologic testing were older and

209 more likely to be non-Hispanic White, college educated, and less likely to be healthcare workers

or essential workers. 4,235 persons underwent serologic testing in Period 1, and 3,615 persons

tested in Period 2. A total of 3,339 persons tested at both time points, including 3,280 who were

seronegative on their antibody test in Period 1 and who could be followed prospectively for the

213 outcome of SARS-CoV-2 seroconversion based on their subsequent serologic test result in the

- study. Differences between those testing in Period 1 and Period 2 were negligible (Table S1).
- The median time between specimen collection dates for both serologic tests was 190 days (IQR
- 216 152-201) (Figure S2).
- 217

Table 1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants

| | | | Participan | ts with |
|------------------------|------------|------------------|------------|----------------|
| | | All participants | | nore |
| | All partic | | | serologic test |
| | N | % | Ν | % |
| Total | 6,745 | 100% | 4459 | 66% |
| Age* | | | | |
| Median (IQR) | 37 (29 | ,51) | 41 (31, | 55) |
| 18-29 | 1804 | 26.75 | 861 | 19.3 |
| 30-39 | 1965 | 29.13 | 1246 | 27.9 |
| 40-49 | 1160 | 17.2 | 846 | 19.0 |
| 50-59 | 792 | 11.74 | 646 | 14.5 |
| 60+ | 1024 | 15.18 | 860 | 19.3 |
| Gender | | | | |
| Male | 3047 | 45.17 | 1991 | 44.7 |
| Female | 3527 | 52.29 | 2337 | 52.4 |
| Non-Binary/Transgender | 171 | 2.54 | 131 | 2.9 |
| Race/Ethnicity* | | | | |
| White Non-Hispanic | 3859 | 56.8 | 2953 | 66.3 |
| Hispanic | 1310 | 19.42 | 669 | 15.0 |
| Black Non-Hispanic | 851 | 12.62 | 369 | 8.3 |
| Asian | 439 | 6.51 | 283 | 6.3 |
| Pacific Islander | 36 | 0.53 | 18 | 0.4 |
| Other | 250 | 3.71 | 167 | 3.8 |
| Education | | | | |
| Less than high school | 123 | 1.82 | 52 | 1.2 |
| High school graduate | 879 | 13.03 | 399 | 9.0 |
| Some college | 1889 | 28.01 | 1126 | 25.3 |
| | | | | |


| College graduate | 3854 | 57.14 | 2882 | 64.6 |
|--------------------------------|------|-------|------|------|
| Employment* | | | | |
| Employed | 4249 | 62.99 | 2741 | 61.5 |
| Out of work | 830 | 12.31 | 535 | 12.0 |
| Homemaker | 352 | 5.22 | 240 | 5.4 |
| Student | 610 | 9.04 | 362 | 8.1 |
| Retired | 704 | 10.44 | 581 | 13.0 |
| Household income* | | | | |
| Less than \$35,000 | 2180 | 32.32 | 1288 | 28.9 |
| \$35-49,999 | 753 | 11.16 | 487 | 10.9 |
| \$50-69,999 | 960 | 14.23 | 635 | 14.2 |
| \$70-99,999 | 1058 | 15.69 | 734 | 16.5 |
| \$100,000+ | 1794 | 26.6 | 1315 | 29.5 |
| Setting* | | | | |
| Urban | 2974 | 44.09 | 1962 | 44.0 |
| Suburban | 1760 | 26.09 | 1143 | 25.6 |
| Rural | 2011 | 29.81 | 1354 | 30.4 |
| Geographic region* | | | | |
| Northeast | 1882 | 27.9 | 1294 | 29.0 |
| Midwest | 1127 | 16.71 | 794 | 17.8 |
| South | 2103 | 31.18 | 1269 | 28.5 |
| West | 1625 | 24.09 | 1097 | 24.6 |
| US Dependent Territories | 8 | 0.12 | 5 | 0.1 |
| Healthcare worker* | | | | |
| No | 5948 | 88.18 | 4042 | 90.7 |
| Yes | 797 | 11.82 | 417 | 9.4 |
| Essential worker | | | | |
| No | 5601 | 83 | 3858 | 86.5 |
| Yes | 1144 | 17 | 601 | 13.5 |
| Higher risk for severe COVID** | | | | |
| No | 3167 | 46.95 | 2074 | 46.5 |
| Yes | 3578 | 53.05 | 2385 | 53.5 |

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

** >60 years old, or reported co-morbidity, or current smoker.

219 Cumulative incidence since the beginning of the pandemic and potential risk factors

- 220 The crude and adjusted serology-based estimates of cumulative incidence of SARS-CoV-2
- infection through the end of observation (January 31, 2021) were 6.8% (95% CI 6.1%-7.6%) and
- 6.3% (95% CI 5.5%-7.1%), respectively (Table S2). Cumulative incidence rates declined in
- dose-response fashion with increasing age, with substantially lower incidence in those aged 60
- 224 years and older (Figure 1). Higher cumulative incidence estimates were observed among males
- 225 (7.8%, 95% CI 6.6%-9.0%), Hispanics 10.2% (95% CI 7.8%-12.6%), non-Hispanic Blacks
- 226 (7.9%, 95% CI 5%-10.8%), those with a high school education (9.1%, 95% CI 0.9-20.9) or less
- 227 (8.0%, 95% CI 5.2-10.9%), and those in the Northeast (7.8%, 95% CI 6.3%-9.4%). Lower
- cumulative incidence estimates were observed among persons aged 60 years and over (3.8%,
- 229 95% CI 2.5%-5.2%), those whose gender identity was non-binary (2.5%, 95% CI 0.4%-5.5%),
- and those who were retired (3.4%, 95% CI 1.7%-4.9%).
- 231




232

Figure 1 shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 by baseline demographic characteristics of CHASING COVID Cohort Study participants. Estimates are adjusted for laboratory test error. Essential workers include people working in in law enforcement, emergency management, delivery, transportation, and construction. High risk group is defined as participants who either reported a comorbidity, were over 60 years old, or were a smoker. The size of the square box/marker is proportional to the overall sample size in each group.

237

The estimated cumulative incidence of SARS-CoV-2 infection by epidemiologic risk factors 238 reported at enrollment are shown in Figure 2 (and in Table S3). Higher cumulative incidence 239 estimates were observed among those who, at cohort enrollment, reported having attended mass 240 gatherings (8.6%, 95% CI 5.8%-12.4%), and lived in more crowded households (8.7%, 95% CI 241 5.7%-13.2%). Those who thought they had COVID-19 in the past, and in Period 2, those who 242 had a known SARS-CoV-2 exposure, sought a test, had a self-reported SARS-CoV-2 diagnosis 243 or COVID-19-related hospitalization also had markedly higher cumulative incidence (Table S3). 244 People living with HIV had the highest cumulative incidence among those with comorbidities 245 (8.8%, 95% CI 5.5%-13.6%) over the entire study period, however, those with diabetes had the 246 highest cumulative incidence in Period 2 (Table S3). In terms of other potential risk factors, 247 those who reported recently drinking more than 6 alcoholic drinks on one occasion (9.9%, 95% 248 CI 6.6%-14.3%) and those who used public transportation (8.6%, 95% CI 5.7%-12.6%) had 249 higher cumulative incidence (Fig. 2, Table S3). Lower cumulative incidence was observed 250 among those who, at enrollment, reported having asthma, immunosuppression, and depression. 251





253

Figure 2 shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 in CHASING COVID Cohort Study participants by

risk factors. Estimates are adjusted for laboratory test kit error. All risk factors were measured at the baseline survey. Alcohol use is defined as having

256 more than 6 drinks on one occasion weekly, daily, or almost daily. (NPIs: Non-pharmaceutical interventions; HH: Household). The size of the square 257 box/marker is proportional to the overall sample size in each group.

258

259 Incidence of recent SARS-CoV-2 seroconversion and potential risk factors

- Figure 3 (and Table S4) shows more recent seroconversions and incidence rates among 3,280
- initially seronegative persons who had a subsequent serologic test during November 2020-
- January 2021 (Fig. S2), stratified by risk factors that were present prior to or between serologic
- tests. There were 145 observed seroconversions over 1,562 person years of follow-up among the
- 3,280 participants, for an overall incidence rate of 9.3 per 100 person years (PY) (95% CI 7.9-
- 11.0). The rate ratio (RR) for incident SARS-CoV-2 infection was higher for males than females
- 266 (RR: 1.34, 95% CI 0.96-1.87), Hispanics (RR: 2.11, 95% CI 1.40-3.12) and non-Hispanic Blacks
- 267 (RR 1.79, 95% CI 0.96-3.13) compared with non-Hispanic Whites. In contrast to cumulative
- incidence estimates, incidence rates reflecting more recent seroconversions were higher among
- those in rural versus urban areas (RR 1.52, 95% CI 1.04-2.22), those in the Midwest (RR 1.62,
- 270 95% CI 0.98-2.69), the South (RR 1.73, 95% CI 1.1-2.75), and the West (RR 1.34, 95% CI 0.79-
- 271 2.2) compared to the Northeast. Of note, essential workers had higher incidence than non-






Figure 3 shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING
 COVID Cohort Study participants by demographic factors. Essential workers include people working in in law enforcement, emergency management,
 delivery, transportation, and construction. High risk group is defined as participants who either reported a comorbidity, were over 60 years old, or were

- a smoker. The size of the square box/marker is proportional to the overall sample size in each group.
- 278

Figure 4 (and Table S5) shows recent seroconversions and incidence rates for epidemiologic 279 risk factors. Living in more crowded households was associated with higher incidence than 280 living in less crowded households (RR 1.61, 95% CI 1.08-2.32). Compared with referent groups 281 282 in Figure 4, there was also higher incidence among those who dined indoors at restaurants/bars (RR 1.95, 95% CI 1.38-2.83); those who visited a place of worship (RR 1.95, 95% CI 1.25-2.93); 283 those who wore a mask only sometimes while grocery shopping (RR 2.49, 95% CI 1.31-4.36); 284 those who visited indoors with people not in their own household while always wearing a mask 285 (RR=2.6; 95% CI 1.6-4.4), while sometimes wearing a mask (RR=3.5; 95% CI 2.7-5.7 or while 286 never wearing a mask (RR=5.3; 95% CI 3.1-8.9); those working indoors at a place of 287 employment while always wearing a mask (RR=2.0, 95% CI 1.4-2.8), while sometimes wearing 288 a mask (RR=2.0, 95% CI 1.1-3.5), or while never wearing a mask RR=3.7, 95% CI 1.3-8.5); 289 those attending a salon or gym with masks (RR=1.7, 95% CI 1.1-2.4); those who gathered 290 indoors and outdoors in groups of >10 (RR=1.9, 95% CI 1.2-2.0); and those that traveled by air 291 during the pandemic (RR 1.72, 95% CI 1.12-2.55). 292

293

| Subgroup | Seronegative at P1 | Incident infections | | Incidence rate /100 | Risk Ratio (95% Cl |
|--|----------------------------|----------------------|---------------------------------------|-----------------------------|---|
| Total | 3280 | 145 | | 9.3 | |
| Household factors Household crowding No household crowding | 785 2495 | 35 110 | | 13.5 8.4 | 1.61 (1.1,2.3) ref |
| Child in household No child in household | 932 2348 | 40 105 | ⊢₽ −1 | 9.5 9.2 | 1.03 (0.7,1.5) ref |
| Confirmed case in household member No confirmed case in household member | 42 82 | 18 25 | · · · · · · · · · · · · · · · · · · · | 0.5 1.7 | ref 3.2 (1.7,6) |
| Social distancing Attended mass gathering(s) Did not attend mass gathering(s) | 337 2943 | 16 129 | F | 9.5 9.2 | 1.03 (0.6,1.7) ref |
| Indoor dining/bar No indoor dining/bar | 1787 1489 | 102 43 | - | 11.9 6.1 | 1.95 (1.4,2.8) ref |
| Outdoor dining/bar No outdoor dining/bar | 1896 1384 | 92 53 | + | 9.7 8.4 | 1.15 (0.8,1.7) ref |
| Visited place of worship Did not visit place of worship | 341 2939 | 26 119 | i → • → • | 16.4 8.4 | 1.95 (1.2,2.9) ref |
| Visited public park/public pool Did not visit public park/pool | 2323 957 | 103 42 | ⊢∎ 1 | 9.1 9.7 | ref 0.94 (0.7,1.4) |
| Mask indoor grocery shopping N/A (Did not go grocery shopping) Always Sometimes Never | 161 2959 128 32 | 8 125 12 0 | | 10.3 8.8 21.9 0 | 1.17 (0.5,2.3) ref 2.49 (1.3,4.4) 0 (0,2.4) |
| Mask indoor visiting non-household members N/A (Did no visit non-household members indoors) Always Sometimes Never | 666 1047 1081 438 | 27 37 51 30 | | 3.9 10.3 13.8 20.6 | ref 2.64 (1.6.4.4) 3.54 (2.2.5.7) 5.28 (3.1.8.9) |
| Mask indoor at work N/A (Did not attend indoor workplace) Always Sometimes Never | 1595 1293 282 61 | 68 59 13 5 | | 6.7 13.4 13.4 24.7 | ref 2 (1.4,2.8) 2 (1.1,3.5) 3.69 (1.3,8.5) |
| Mask indoor at salon/gym N/A (Did not attend salon/gym) Always Sometimes Never | 2426 699 31 75 | 106 32 3 4 | | 8.2 13.5 30.3 16.3 | ref 1.65 (1.1,2.4) 3.7 (0.9.10.3) 1.99 (0.6,4.9) |
| Outdoor mask use Mask use outdoors No mask use outdoors | 1501 1779 | 65 80 | ⊢∎-1 | 9.1 9.5 | 0.96 (0.7,1.3) ref |
| Gathered outside in groups >=10 No Indoors only Outdoors only Indoors and cutdoors | 1897 224 661 498 | 66 11 35 33 | | 7.3 10.5 10.9 14 | ref 1.43 (0.7,2.6) 1.48 (1,2.2) 1.9 (1.2,2.9) |
| Movement during the pandemic Avoided Public Transit Did not avoid | 2628 652 | 113 32 | F=1 | 9 10.3 | ref 1.14 (0.8,1.7) |
| Recent Airtravel (Aug-Nov) No recent Airtravel | 410 2870 | 29 116 | 0 1 2 3 4 5 6 | 14.6 8.5 7 | 1.72 (1.1,2.5) ref |

²⁹⁴

Figure 4 shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING COVID Cohort Study participants by behavioral risk factors. For indoor mask use behavior, participants that did not engage in the respective behaviors were classified as N/A. The size of the square box/marker is proportional to the overall sample size in each group.

298

299 Clinical and public health outcomes among persons with serologic evidence of SARS-CoV-

300 2 infection

Among the 303 individuals who were positive for Total Ab during the study, only 121 (39.9%) 301 302 were aware that they had a prior SARS-CoV-2 infection (Table S6). A substantial proportion of the 303 (27.4%) recalled no symptoms of COVID-like illness (i.e., were asymptomatic cases). 303 Among the 145 more recent seroconverters in Period 2, the proportion reporting no symptoms 304 was 25.5%, and another 60% reported milder symptoms that did not result in seeking care. 305 In terms of public health outcomes, 64.4% (195/303) said that they were tested for SARS-306 CoV-2 outside the study (Table S6), half of them (32% of total) reported having a positive 307 308 SARS-CoV-2 test. However, only 30.7% of all 303 seropositives said that they had isolated themselves from people outside their household because of their infection, and, among those 309 310 who did not live alone, even fewer (13.5% overall) said they isolated themselves from others within their household. In terms of contact tracing, 17.8% of all seropositives were asked about 311

contacts following diagnosis and only 12.2% of all seropositives had been informed by a contact

tracer that they may have had contact with someone confirmed to have SARS-CoV-2. Only 5.3%

of those diagnosed (3.3% of all seropositives) were told by a contact tracer to stay home for a

- 315 period of time because they had COVID-19.
- 316

317 Repeat serologic testing outcomes

A total of 303 persons who were ever seropositive by the Total Ab test contributed 392 318 seropositive Total Ab test results over the course of the study (Table S7). This included 134 319 persons with a positive Total Ab test in Period 1 and 258 in Period 2. Of the 258 Total Ab 320 positives in Period 2, 145 were recent seroconverters. There were 20 individuals who were Total 321 Ab positive in Period 1 but Total Ab negative in Period 2 (i.e., seroreverters and/or false 322 positives). Specifically, of 134 persons who tested Total Ab positive in Period 1 and had a 323 second test in Period 2, only 114 (85%) were still seropositive in Period 2. The median time 324 between specimen collection for these 20 individuals was 197 days (IQR 187-201 days). Of the 325 392 specimens that were positive on the Total Ab test from Period 1 or 2, 361 had sufficient 326 327 specimen quantity for further testing. Of these, 63.4% (201/361) were also positive on the spike protein-based IgG test, including 65.7% (88/127) in Period 1, and 42.1% (113/234) in Period 2 328 (Table S7). 329

330

331 **DISCUSSION**

We report findings from one of the first community-based prospective epidemiologic studies 332 of SARS-CoV-2 incidence and risk factors, globally. We have prospectively characterized the 333 risk of incident SARS-CoV-2 infection in relation to a range of modifiable risk factors in the 334 335 U.S., using information on both past infection and recent seroconversion. With a wellcharacterized sample of participants with evidence of prior infection, our study suggests that 336 public health strategies being widely used with the aim of reducing onward transmission 337 (quarantine, testing, isolation, and contact tracing) do not have high enough coverage during the 338 339 infectious period of SARS-CoV-2 to be effective at controlling community spread. These are among the principal reasons why the U.S. has seen unmitigated increases in 340 community transmission, hospitalizations, and deaths from COVID-19. Unless and until herd 341 342 immunity can be achieved through a combination of natural infection and vaccine-induced

immunity, more nuanced understanding of the actual contribution of these factors over time is 343 needed. This in turn will facilitate more effective government and community public health 344 policies, actions and implementation strategies to control community spread, which is key to 345 preventing avoidable hospitalizations and deaths, and ultimately maximizing the impact of 346 vaccines. In areas where there is not an enforced lock down, our findings provide an evidence-347 base for federal, state, and local policy focus on risk factors that appear to be potential drivers of 348 late-phase pandemic spread, such as indoor dining, mass gatherings, or not wearing masks when 349 outside the home. 350

Data on more recent seroconversions occurring between May 2020 and January 2021 in our 351 cohort suggest that elevated risk among essential workers, observed early in the U.S. pandemic, 352 has persisted. Essential workers risk exposure to SARS-CoV-2 not only in their workplace(s), 353 but also in their communities and as part of their commutes to and from work if they need to use 354 public transportation. The increased burden of risk of SARS-CoV-2 infection in essential 355 workers is then shared with their household members, among whom transmission is very 356 efficient.¹⁹ Along with this comes a higher burden of stress and anxiety among essential 357 workers.²⁰ The most immediate action that governments can take to help keep essential workers 358 safe is to minimize community transmission so that they are less likely to be exposed in the 359 workplace or as part of their commutes. Policies and other strategies should be considered and 360 implemented to ensure workplace safety (high quality masks, distancing, ventilation, paid sick 361 362 leave for those that cannot afford to miss work) and the safety of public transportation. Any strategies should include prioritized access to SARS-CoV-2 vaccines for essential workers and, 363 until or in the absence of vaccination, rapid testing for essential workers and members of their 364 households. FDA-approved fully at-home rapid testing options are becoming more readily 365 366 available with or without a prescription, and past research has indicated an overall increase in the uptake of testing with the addition of at-home testing options,^{21,22} making them a potentially 367 important strategy to increase early identification of new infections and subsequent interventions 368 to prevent onward transmission. In this later phase of the pandemic, healthcare workers in our 369 370 cohort had borderline elevated risk. Healthcare workers in the U.S. could be expected to have lower risk of SARS-CoV-2 exposure in the workplace due to focused efforts to mitigate risk via 371 improved access to personal protective equipment and engineering controls. However, healthcare 372

373 workers also have ongoing community exposure, including possibly during their commutes to and from work, that could put them at higher risk of SARS-CoV-2 exposure and acquisition. 374 375 Our study provides epidemiologic evidence of increased risk for a number of key exposures. Living in more crowded households, defined as living in a multi-unit (i.e., apartment) building 376 with 4 or more household members, was associated with a 60% higher incidence of SARS-CoV-377 2 infection compared with those living in less crowded households. Household transmission of 378 SARS-CoV-2 occurs with very high attack rates, and may also increase the risk of more severe 379 COVID-19 disease, requiring hospitalization.²³ Household crowding, more than population 380 density, was shown to be a characteristic of community transmission 'hotspots' in a recent 381 ecological analysis from the early phase of the pandemic.²⁴ When there are possible or confirmed 382 cases of SARS-CoV-2 among household members, when background community transmission is 383 substantial, or when the possibility of exposure outside the household is high (e.g., essential 384 workers), our study and others²⁵ suggest mask use in the household should be considered, 385 especially when it is otherwise not possible to limit potential exposure and spread in the 386 household by isolating or sequestering away from others. As the vaccine rollout continues, this is 387 particularly important to protect unvaccinated household members who may be at high risk for a 388 severe COVID-19 outcome. 389

We characterized the potential contribution of several other key risk factors, some of which 390 have been, or could be, the focus of state and federal policies, including dining indoors at a 391 392 restaurant/bar, visiting a place of worship, inconsistent mask use while grocery shopping or visiting non-household members indoors (especially without masks), visiting a salon/gym, 393 gathering indoors in groups of 10 or more, and recent travel by airplane during the pandemic. 394 Working indoors, even while always masking but especially while never wearing a mask, was 395 396 strongly associated with higher infection rates. In addition to being potential individual policy focus areas, we note that all of these risks can be mitigated by social distancing, workplace 397 safety, increased mask use, use of more effective masks (e.g., KN95), and use of more than one 398 mask.^{26–28} 399

Finally, detailed examination of 303 individuals with serologic evidence of past SARS-CoV-2 infection showed major gaps in the reach of public health interventions aimed at testing, selfisolation, and contact tracing for people with SARS-CoV-2 (and their contacts). Indeed, many with evidence of prior SARS-CoV-2 infection did not report a prior positive PCR test, and a

substantial proportion were asymptomatic, both greatly hindering the ability of public health 404 efforts to control spread. Furthermore, few people who had evidence of prior SARS-CoV-2 405 infection in our study reported having been reached by contact tracers. When considering the 406 large proportion of people with SARS-CoV-2 who have asymptomatic infection, undiagnosed 407 infection (with or without symptoms), the low likelihood of diagnosis during the pre-408 symptomatic phase, the high number of new daily diagnoses and the often long delay between 409 testing and return of results, contact tracing (a strategy that requires rapid response and action 410 with high coverage early in the infectious period) is likely not a feasible strategy to control 411 community spread in the U.S.. Limited public health resources may be better spent instead on 412 messaging that emphasizes the importance of self-isolation after symptom onset or a positive 413 test. Verbal, written and electronic (SMS text, email) messaging should occur at the time of the 414 test, rather than after results are returned. In the event of a positive result, messaging at the time 415 of testing should also include instructions to notify close contacts, including in workplaces, that 416 they should quarantine and, if symptoms develop, self-isolate. 417

A shift in emphasis and resources away from contact tracing as a strategy to control community spread would provide much needed resources at the state and local level to facilitate more rapid and targeted delivery of vaccination, which has faltered in many areas to date. Many in our cohort, as across the U.S., are not yet vaccinated, not yet eligible for or are not currently willing to undergo vaccination²⁹, and will remain at risk for months to come. Accelerating vaccine rollout, especially among those at high risk for a severe SARS-CoV-2 outcome and essential workers, has the potential to save tens of thousands of lives.

425 All of the potential risk factors described in our study and the low uptake of public health strategies conspire to create a perpetually disparate burden of risk among Hispanic and non-426 427 Hispanic Black persons and essential workers, as well as their household members and their communities. Our study suggests these inequalities have not been addressed to date in the U.S., 428 and the ultimate drivers, which relate to structural racism and possibly other factors, need to be 429 unpacked by health departments and researchers.³⁰ There has been much research focused on 430 comorbid medical conditions and other biologic factors that may increase the risk of SARS-431 CoV-2 acquisition or severity.^{31–33} However, non-biological structural factors are the major 432 drivers of COVID-19 infection and severe outcomes, and the inequities by race/ethnicity, 433 occupation, geography, and income. These non-biological structural factors, such as household 434

crowding, the need to go to work to avoid income loss, and inequitable access to SARS-CoV-2 435 testing³⁴, create a disparate burden of SARS-CoV-2 exposure and incidence.³⁵ To date, no 436 437 targeted strategies or policies have been deployed that aim to protect those who cannot afford missing work, including, but not only, essential workers. These disparities in SARS-CoV-2 438 exposure, incidence, hospitalization and death will likely be perpetuated and likely exacerbated 439 by differential uptake of the COVID-19 vaccines, driven by potentially flawed implementation 440 strategies that prevent equitable access to vaccination. It is incumbent upon public health leaders, 441 decision makers, and policy makers to anticipate and proactively design pandemic response 442 implementation strategies, including metrics, that account for and counteract the fundamental 443 and prevailing structural forces that without fail will otherwise create, perpetuate, or exacerbate 444 inequities in safety, health and well-being.^{36–39} 445

Strengths of our cohort study include its prospective design, allowing direct observation of seroconversions and incident COVID-19 infection among those who had no serologic evidence of prior SARS-CoV-2 infection, with and without risk factors. Our cohort is also geographically and sociodemographically diverse, facilitating assessment of geographic differences and racial/ethnic disparities. We also measured and were able to estimate incidence rates associated with a range of relevant epidemiologic risk factors.

Our study also has limitations worth noting. Most research studies deployed in the middle of 452 a pandemic, including ours, may produce biased estimates since they may not include complete 453 454 information on participants who died from COVID-19, or were too sick or otherwise too busy to participate in the research activities, or enrolled but became lost to follow-up. Moreover, it is 455 possible that those who thought they had SARS-CoV-2 or were tested outside the study may 456 have been more or less likely to participate in follow-up serologic testing, which would lead our 457 458 seroincidence estimates to be biased in either direction. However, there was no systematic difference between those who tested in Period 1 and Period 2 (Table S1). Separately, while we 459 have corrected our cumulative incidence estimates for laboratory test error¹⁸, the *observed* 460 cumulative incidence in our cohort may be lower than the *true* cumulative incidence in our 461 cohort because of waning of SARS-CoV-2 antibodies. Recent studies suggest waning of 462 antibodies to both nucleocapsid and spike proteins², which combined with the timing of 463 specimen collection relative to infection for many participants in our cohort (median of 190 464 days)⁹, could mean that we have underestimated the true cumulative incidence. Next, as with any 465

observational cohort study, estimated associations between SARS-CoV-2 risk factors and 466 incidence are subject to confounding. The crude associations we presented could be over- or 467 underestimated, and also may vary by setting. For example, the effect of indoor dining may be 468 different in areas of lower versus higher levels of community transmission. Our study also had 469 limited statistical power due to our sample size and the relatively short duration of follow-up. 470 Finally, while our study is well-suited to characterize the risks related to SARS-CoV-2 471 acquisition, it is less well-suited to examine factors related to onward transmission from 472 participants who had SARS-CoV-2 infection. However, in lieu of this, we have endeavored to 473 describe the coverage of public health-related outreach to persons in our cohort who had 474 evidence of past SARS-CoV-2 infection and identified some areas in need of improvement, such 475 as the need for improvements in the uptake of testing and self-isolation. 476

477

478 Conclusion

Modifiable risk factors and poor reach of public health strategies continue to drive transmission 479 of SARS-CoV-2 across the U.S.. It is critical to address inequities in incidence, reduce risk 480 481 factors, and improve the reach of public health strategies of testing and self-isolation in the vaccine era. Given the properties of the SARS-CoV-2 virus, including the substantial 482 asymptomatic and pre-symptomatic phases during the SARS-CoV-2 infectious period, the 483 magnitude of cases and the need to act quickly, contact tracing is not a viable public health 484 485 strategy to control the spread of the pandemic in the U.S.. Our cumulative incidence estimates suggest that many in our cohort remain at risk for SARS-CoV-2, including those with risk factors 486 for infection and severe disease. While SARS-CoV-2 vaccines will likely reduce the risk of 487 COVID-19 disease and possibly SARS-CoV-2 acquisition substantially for this group, this will 488 489 likely take some time due to both the pace of the vaccine rollout and vaccine hesitancy. The CHASING COVID Cohort Study will continue to monitor SARS-CoV-2 outcomes, including 490 vaccine uptake, through December 2021. 491

492

493

494 **CONTRIBUTORS**

495 DN, MR, SGK, MMR, conceptualized the study. MR, MC and DN performed statistical

analyses. DN and MR wrote the first draft of the paper. DN, MR, MC, SGK, and AP contributed

- 497 to interpreting the data, DN, RZ, MR, MC, SGK, WY, AB, CM, SK, AM, MMR, DW, AP, LW,
- 498 CG and to the writing and revising of the manuscript, SGK, WY, AB, CM, SK, and DN
- 499 contributed to data collection, cleaning and management. DN, SGK, MMR and CG contributed
- 500 to obtaining funding for the research.
- 501

502 ACKNOWLEDGEMENTS

- 503 The authors wish to thank the participants of the CHASING COVID Cohort Study. We are
- grateful to you for your contributions to the advancement of science around the SARS-CoV-2
- pandemic. We thank Prof. Patrick Sullivan and MTL for local validation work on the serologic
- assays for use with DBS that greatly benefited our study. We are also grateful to MTL Labs for
- 507 processing specimen collection kits and serologic testing of our cohort's specimens.
- 508

509 FUNDING

- 510 Funding for this project is provided by The National Institute of Allergy and Infectious Diseases
- 511 (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the
- 512 CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the
- 513 COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy,
- and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina
- 515 Population Center).

516 **REFERENCES**

| 1. CDC, COVID Data Tracker (2020), (available at https://covid.cdc.gov/covid-data-tr | acker/ |). |
|--|--------|----|
|--|--------|----|

- 518 2. K. L. Bajema, R. E. Wiegand, K. Cuffe, S. V. Patel, R. Iachan, T. Lim, A. Lee, D. Moyse, F. P. Havers, L. Harding, A. M. Fry, A. J. Hall, K. Martin, M. Biel, Y. Deng, W. A. Meyer 3rd, 519 520 M. Mathur, T. Kyle, A. V. Gundlapalli, N. J. Thornburg, L. R. Petersen, C. Edens, Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern. 521 522 Med. (2020), doi:10.1001/jamainternmed.2020.7976. 3. F. J. Angulo, L. Finelli, D. L. Swerdlow, Estimation of US SARS-CoV-2 Infections, 523 524 Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA Netw Open. 4, e2033706 (2021). 525 526 4. H. Kalish, C. Klumpp-Thomas, S. Hunsberger, H. A. Baus, M. P. Fay, N. Siripong, J. Wang, J. Hicks, J. Mehalko, J. Travers, M. Drew, K. Pauly, J. Spathies, T. Ngo, K. M. Adusei, M. 527 Karkanitsa, J. A. Croker, Y. Li, B. I. Graubard, L. Czajkowski, O. Belliveau, C. Chairez, K. 528 Snead, P. Frank, A. Shunmugavel, A. Han, L. T. Giurgea, L. A. Rosas, R. Bean, R. Athota, 529 530 A. Cervantes-Medina, M. Gouzoulis, B. Heffelfinger, S. Valenti, R. Caldararo, M. M. Kolberg, A. Kelly, R. Simon, S. Shafiq, V. Wall, S. Reed, E. W. Ford, R. Lokwani, J.-P. 531 Denson, S. Messing, S. G. Michael, W. Gillette, R. P. Kimberly, S. E. Reis, M. D. Hall, D. 532 Esposito, M. J. Memoli, K. Sadtler, Mapping a Pandemic: SARS-CoV-2 Seropositivity in 533 the United States. medRxiv (2021), doi:10.1101/2021.01.27.21250570. 534 5. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. Ipekci, G. 535 Salanti, N. Low, Occurrence and transmission potential of asymptomatic and 536 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. 537 PLoS Med. 17, e1003346 (2020). 538 539 6. H. J. Hutchins, B. Wolff, R. Leeb, J. Y. Ko, E. Odom, J. Willey, A. Friedman, R. H. Bitsko, COVID-19 Mitigation Behaviors by Age Group - United States, April-June 2020. MMWR 540 Morb. Mortal. Wkly. Rep. 69, 1584–1590 (2020). 541
- 542 7. M. Lipsitch, D. L. Swerdlow, L. Finelli, Defining the epidemiology of Covid-19—studies

21

543 needed. N. Engl. J. Med. **382**, 1194–1196 (2020).

- 544 8. D. P. Oran, E. J. Topol, The Proportion of SARS-CoV-2 Infections That Are Asymptomatic
 545 : A Systematic Review. *Ann. Intern. Med.* (2021), doi:10.7326/M20-6976.
- M. Robertson, S. Kulkarni, A. Berry, C. Mirzayi, A. R. Maroko, R. Zimba, D.
 Westmoreland, C. Grov, A. Parcesepe, L. Waldron, D. Nash, A national prospective cohort
 study of SARS/COV2 pandemic outcomes in the U.S.: The CHASING COVID Cohort.
 medRxiv (2020), doi:10.1101/2020.04.28.20080630.
- 10. C. Grov, D. A. Westmoreland, P. B. Carneiro, M. Stief, C. MacCrate, C. Mirzayi, D. W.
 Pantalone, V. V. Patel, D. Nash, Recruiting vulnerable populations to participate in HIV
 prevention research: findings from the Together 5000 cohort study. *Annals of Epidemiology*.
 35 (2019), pp. 4–11.
- D. Nash, M. Stief, C. MacCrate, C. Mirzayi, V. V. Patel, D. Hoover, D. W. Pantalone, S.
 Golub, G. Millett, A. B. D'Angelo, D. A. Westmoreland, C. Grov, A Web-Based Study of
 HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative
 Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for
 an Observational Cohort Study. *JMIR Research Protocols.* 8 (2019), p. e13715.
- 12. C. Grov, D. Westmoreland, H. J. Rendina, D. Nash, Seeing Is Believing? Unique
 Capabilities of Internet-Only Studies as a Tool for Implementation Research on HIV
 Prevention for Men Who Have Sex With Men: A Review of Studies and Methodological
 Considerations. J. Acquir. Immune Defic. Syndr. 82 Suppl 3, S253–S260 (2019).
- 563 13. CDC BRFSS (2020), (available at https://www.cdc.gov/brfss/index.html).
- 14. T. A. Santibanez, J. A. Singleton, S. S. Santibanez, P. Wortley, B. P. Bell, Sociodemographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal
 influenza vaccination and disease among adults during the 2009--2010 influenza season. *Influenza Other Respi. Viruses.* 7, 383–392 (2013).
- 568 15. S. Kumar, S. C. Quinn, K. H. Kim, L. H. Daniel, V. S. Freimuth, The impact of workplace
 569 policies and other social factors on self-reported influenza-like illness incidence during the

22

| 570 | | 2009 H1N1 pandemic. Am. J. Public Health. 102, 134–140 (2012). |
|-----|-----|--|
| 571 | 16. | M. T. Niles, R. Neff, E. Biehl, F. Bertmann, E. H. Morgan, T. Wentworth, Food Access and |
| 572 | | Security During Coronavirus Survey- Version 1.0 (2020), , doi:10.7910/DVN/RQ6NMG. |
| 573 | 17. | Center for Devices, Radiological Health, EUA Authorized Serology Test Performance |
| 574 | | (2021), (available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid- |
| 575 | | 19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test- |
| 576 | | performance). |
| 577 | 18. | C. T. Sempos, L. Tian, Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit |
| 578 | | Error. Am. J. Epidemiol. 190, 109–115 (2021). |
| 579 | 19. | Z. J. Madewell, Y. Yang, I. M. Longini Jr, M. E. Halloran, N. E. Dean, Household |
| 580 | | Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Netw Open. |
| 581 | | 3 , e2031756 (2020). |
| 582 | 20. | A. M. Parcesepe, M. Robertson, A. Berry, A. Maroko, R. Zimba, C. Grov, D. |
| 583 | | Westmoreland, S. Kulkarni, M. Rane, W. Salgado-You, C. Mirzayi, L. Waldron, D. Nash, |
| 584 | | The relationship between anxiety, health, and potential stressors among adults in the United |
| 585 | | States during the COVID-19 pandemic. <i>medRxiv</i> (2020), doi:10.1101/2020.10.30.20221440. |
| 586 | 21. | R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. Parcesepe, L. |
| 587 | | Waldron, M. Rane, S. Kochhar, M. Robertson, A. Maroko, C. Grov, D. Nash, SARS-CoV-2 |
| 588 | | Testing Service Preferences of Adults in the United States: Discrete Choice Experiment. |
| 589 | | JMIR Public Health Surveill. 6, e25546 (2020). |
| 590 | 22. | M. L. Romo, R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. |
| 591 | | M. Parcesepe, L. Waldron, M. Rane, S. Kochhar, M. Robertson, A. R. Maroko, C. Grov, D. |
| 592 | | Nash, Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States. |
| 593 | | medRxiv (2020), doi:10.1101/2020.12.22.20248747. |
| 594 | 23. | D. Nash, S. Qasmieh, M. Robertson, M. Rane, R. Zimba, S. Kulkarni, A. Berry, W. You, C. |
| 595 | | Mirzayi, D. Westmoreland, A. Parcesepe, L. Waldron, S. Kochhar, A. R. Maroko, C. Grov, |
| 596 | | Household factors and the risk of severe COVID-like illness early in the US pandemic. |

medRxiv (2020), doi:10.1101/2020.12.03.20243683.

- 598 24. A. Maroko, D. Nash, B. Pavlonis, Covid-19 and Inequity: A comparative spatial analysis of
 599 New York City and Chicago hot spots. *J. Urban Health* (2020).
- Y. Wang, H. Tian, L. Zhang, M. Zhang, D. Guo, W. Wu, X. Zhang, G. L. Kan, L. Jia, D.
 Huo, B. Liu, X. Wang, Y. Sun, Q. Wang, P. Yang, C. R. MacIntyre, Reduction of secondary
 transmission of SARS-CoV-2 in households by face mask use, disinfection and social
 distancing: a cohort study in Beijing, China. *BMJ Glob Health*. 5 (2020),
 doi:10.1136/bmjgh-2020-002794.
- 605 26. CDC, Scientific brief: Community use of cloth masks to control the spread of SARS-CoV-2
 606 (2020), (available at https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science 607 sars-cov2.html).
- Y. Li, M. Liang, L. Gao, M. Ayaz Ahmed, J. P. Uy, C. Cheng, Q. Zhou, C. Sun, Face masks
 to prevent transmission of COVID-19: A systematic review and meta-analysis. *Am. J. Infect. Control* (2020), doi:10.1016/j.ajic.2020.12.007.
- 28. D. K. Chu, E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schünemann, COVID-19
 Systematic Urgent Review Group Effort (SURGE) study authors, Physical distancing, face
 masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and
 COVID-19: a systematic review and meta-analysis. *Lancet.* 395, 1973–1987 (2020).
- 615 29. K. A. Fisher, S. J. Bloomstone, J. Walder, S. Crawford, H. Fouayzi, K. M. Mazor, Attitudes
 616 Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann. Intern. Med.* 173,
 617 964–973 (2020).
- 30. L. N. Borrell, J. R. Elhawary, E. Fuentes-Afflick, J. Witonsky, N. Bhakta, A. H. B. Wu, K.
 Bibbins-Domingo, J. R. Rodríguez-Santana, M. A. Lenoir, J. R. Gavin 3rd, R. A. Kittles, N.
 A. Zaitlen, D. S. Wilkes, N. R. Powe, E. Ziv, E. G. Burchard, Race and Genetic Ancestry in
 Medicine A Time for Reckoning with Racism. *N. Engl. J. Med.* 384, 474–480 (2021).
- A. Emami, F. Javanmardi, N. Pirbonyeh, A. Akbari, Prevalence of underlying diseases in
 hospitalized patients with COVID-19: a systematic review and meta-analysis. *Archives of*

| 624 | | academic emergency medicine. 8 (2020) (available at |
|-----|-----|---|
| 625 | | https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7096724/). |
| 626 | 32. | S. Richardson, J. S. Hirsch, M. Narasimhan, J. M. Crawford, T. McGinn, K. W. Davidson, |
| 627 | | the Northwell COVID-19 Research Consortium, D. P. Barnaby, L. B. Becker, J. D. Chelico, |
| 628 | | S. L. Cohen, J. Cookingham, K. Coppa, M. A. Diefenbach, A. J. Dominello, J. Duer-Hefele, |
| 629 | | L. Falzon, J. Gitlin, N. Hajizadeh, T. G. Harvin, D. A. Hirschwerk, E. J. Kim, Z. M. Kozel, |
| 630 | | L. M. Marrast, J. N. Mogavero, G. A. Osorio, M. Qiu, T. P. Zanos, Presenting |
| 631 | | Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With |
| 632 | | COVID-19 in the New York City Area. JAMA. 323, 2052–2059 (2020). |
| 633 | 33. | C. M. Petrilli, S. A. Jones, J. Yang, H. Rajagopalan, L. O'Donnell, Y. Chernyak, K. A. |
| 634 | | Tobin, R. J. Cerfolio, F. Francois, L. I. Horwitz, Factors associated with hospital admission |
| 635 | | and critical illness among 5279 people with coronavirus disease 2019 in New York City: |
| 636 | | prospective cohort study. BMJ. 369, m1966 (2020). |
| 637 | 34. | A. Mody, K. Pfeifauf, E. H. Geng, Using Lorenz Curves to Measure Racial Inequities in |
| 638 | | COVID-19 Testing. JAMA Netw Open. 4, e2032696 (2021). |
| 639 | 35. | G. Ogedegbe, J. Ravenell, S. Adhikari, M. Butler, T. Cook, F. Francois, E. Iturrate, G. Jean- |
| 640 | | Louis, S. A. Jones, D. Onakomaiya, C. M. Petrilli, C. Pulgarin, S. Regan, H. Reynolds, A. |
| 641 | | Seixas, F. M. Volpicelli, L. I. Horwitz, Assessment of Racial/Ethnic Disparities in |
| 642 | | Hospitalization and Mortality in Patients With COVID-19 in New York City. JAMA Netw |
| 643 | | <i>Open.</i> 3 , e2026881 (2020). |
| 644 | 36. | D. Nash, E. Geng, Goal-Aligned, Epidemic Intelligence for the Public Health Response to |
| 645 | | the COVID-19 Pandemic. Am. J. Public Health. 110, 1154–1156 (2020). |
| 646 | 37. | D. Nash, Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the |
| 647 | | Public Health Threat Posed by HIV Epidemics. Am. J. Public Health. 110, 53–57 (2020). |
| 648 | 38. | Z. D. Bailey, J. M. Feldman, M. T. Bassett, How Structural Racism Works - Racist Policies |
| 649 | | as a Root Cause of U.S. Racial Health Inequities. N. Engl. J. Med. (2020), |
| 650 | | doi:10.1056/NEJMms2025396. |

25

- 651 39. Z. D. Bailey, N. Krieger, M. Agénor, J. Graves, N. Linos, M. T. Bassett, Structural racism
- and health inequities in the USA: evidence and interventions. *Lancet.* **389**, 1453–1463

653 (2017).

SUPPLEMENTAL MATERIALS




Fig. S1.

Geographic distribution of CHASING COVID Cohort participants, N=6,745




Fig. S2.

Timing of first (red) and second (blue) dried blood spot specimen collection in the CHASING COVID Cohort Study, including follow-up interview milestones

| | All partic | Participants with one or mor All participants serologic test | | or more | Particij with a ser test in Pe (May-Sep 2020 | rologic eriod 1 tember | Participants with a serologic test in Period 2 (November 2020- January 2021)* | | |
|------------------------|------------|--|---------|---------|--|------------------------------|---|-------|--|
| | N | % | Ν | % | Ν | % | Ν | % | |
| Total | 6,745 | 100% | 4459 | 66% | 4235 | 63% | 3615 | 54% | |
| Age* | | | | | | | | | |
| Median (IQR) | 37 (29 | ,51) | 41 (31, | , 55) | 41, (32 | , 56) | 41, (32 | , 56) | |
| 18-29 | 1804 | 26.75 | 861 | 19.3 | 801 | 18.9 | 656 | 18.4 | |
| 30-39 | 1965 | 29.13 | 1246 | 27.9 | 1177 | 27.8 | 1004 | 27.8 | |
| 40-49 | 1160 | 17.2 | 846 | 19.0 | 809 | 19.1 | 686 | 19.0 | |
| 50-59 | 792 | 11.74 | 646 | 14.5 | 620 | 14.6 | 541 | 15.0 | |
| 60+ | 1024 | 15.18 | 860 | 19.3 | 828 | 19.6 | 719 | 19.9 | |
| Gender | | | | | | | | | |
| Male | 3047 | 45.17 | 1991 | 44.7 | 1900 | 44.9 | 1607 | 44.5 | |
| Female | 3527 | 52.29 | 2337 | 52.4 | 2212 | 52.2 | 1906 | 52.7 | |
| Non-Binary/Transgender | 171 | 2.54 | 131 | 2.9 | 123 | 2.9 | 102 | 2.8 | |
| Race/Ethnicity* | | | | | | | | | |
| Non-Hispanic White | 3859 | 56.8 | 2953 | 66.3 | 2833 | 66.9 | 2410 | 66.7 | |
| Hispanic | 1310 | 19.42 | 669 | 15.0 | 623 | 14.7 | 550 | 15.2 | |
| Non-Hispanic Black | 851 | 12.62 | 369 | 8.3 | 342 | 8.1 | 285 | 7.9 | |
| Asian | 439 | 6.51 | 283 | 6.3 | 262 | 6.2 | 228 | 6.3 | |
| Pacific Islander | 36 | 0.53 | 18 | 0.4 | 18 | 0.4 | 15 | 0.4 | |
| Other | 250 | 3.71 | 167 | 3.8 | 157 | 3.7 | 127 | 3.5 | |
| Education | | | | | | | | | |
| Less than high school | 123 | 1.82 | 52 | 1.2 | 47 | 1.1 | 43 | 1.2 | |
| High school graduate | 879 | 13.03 | 399 | 9.0 | 367 | 8.7 | 308 | 8.5 | |
| Some college | 1889 | 28.01 | 1126 | 25.3 | 1053 | 24.9 | 871 | 24.1 | |

Table S1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

| College graduate | 3854 | 57.14 | 2882 | 64.6 | 2768 | 65.4 | 2393 | 66.2 |
|--------------------------------|------|-------|------|------|------|------|------|------|
| Employment* | | | | | | | | |
| Employed | 4249 | 62.99 | 2741 | 61.5 | 2613 | 61.7 | 2216 | 61.3 |
| Out of work | 830 | 12.31 | 535 | 12.0 | 503 | 11.9 | 429 | 11.9 |
| Homemaker | 352 | 5.22 | 240 | 5.4 | 225 | 5.3 | 194 | 5.4 |
| Student | 610 | 9.04 | 362 | 8.1 | 330 | 7.8 | 283 | 7.8 |
| Retired | 704 | 10.44 | 581 | 13.0 | 564 | 13.3 | 493 | 13.6 |
| Household income* | | | | | | | | |
| Less than \$35,000 | 2180 | 32.32 | 1288 | 28.9 | 1213 | 28.6 | 1009 | 27.9 |
| \$35-49,999 | 753 | 11.16 | 487 | 10.9 | 457 | 10.8 | 402 | 11.1 |
| \$50-69,999 | 960 | 14.23 | 635 | 14.2 | 600 | 14.2 | 532 | 14.7 |
| \$70-99,999 | 1058 | 15.69 | 734 | 16.5 | 706 | 16.7 | 624 | 17.3 |
| \$100,000+ | 1794 | 26.6 | 1315 | 29.5 | 1259 | 29.7 | 1048 | 29.0 |
| Setting* | | | | | | | | |
| Urban | 2974 | 44.09 | 1962 | 44.0 | 1873 | 44.2 | 1572 | 43.5 |
| Suburban | 1760 | 26.09 | 1143 | 25.6 | 1092 | 25.8 | 928 | 25.7 |
| Rural | 2011 | 29.81 | 1354 | 30.4 | 1270 | 30.0 | 1115 | 30.8 |
| Geographic region* | | | | | | | | |
| Northeast | 1882 | 27.9 | 1294 | 29.0 | 1244 | 29.4 | 1023 | 28.3 |
| Midwest | 1127 | 16.71 | 794 | 17.8 | 760 | 18.0 | 655 | 18.1 |
| South | 2103 | 31.18 | 1269 | 28.5 | 1188 | 28.1 | 1037 | 28.7 |
| West | 1625 | 24.09 | 1097 | 24.6 | 1038 | 24.5 | 896 | 24.8 |
| US Dependent Territories | 8 | 0.12 | 5 | 0.1 | 5 | 0.1 | 4 | 0.1 |
| Healthcare worker* | | | | | | | | |
| No | 5948 | 88.18 | 4042 | 90.7 | 3835 | 90.6 | 3283 | 90.8 |
| Yes | 797 | 11.82 | 417 | 9.4 | 400 | 9.5 | 332 | 9.2 |
| Essential worker | | | | | | | | |
| No | 5601 | 83 | 3858 | 86.5 | 3662 | 86.5 | 3137 | 86.8 |
| Yes | 1144 | 17 | 601 | 13.5 | 573 | 13.5 | 478 | 13.2 |
| Higher risk for severe COVID** | | | | | | | | |
| No | 3167 | 46.95 | 2074 | 46.5 | 1974 | 46.6 | 1669 | 46.2 |
| Yes | 3578 | 53.05 | 2385 | 53.5 | 2261 | 53.4 | 1946 | 53.8 |

value for this variable ** >60 years old, or reported co-morbidity, or current smoker.

Table S1.

Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

| All unique participants with a serologic test result (Period 1 or Period 2) N=4,459 | | | | | Participants with a serologic test in Period 1 (N=4,235) | | | | Participants with a serologic test in Period 2 (N=3,615) | | | |
|--|---|---|--|---|--|---|---|--|--|---|---|--|
| Number positive | Total | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | Number positive | Total | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | Number positive | Total | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | |
| 303 | 4459 | 6.8 (6.1, 7.6) | 6.3 (5.5, 7.1) | 134 | 4235 | 3.2 (2.6, 3.7) | 2.6 (2, 3.1) | 258 | 3615 | 7.2 (6.3, 8) | 6.7 (5.8, 7.5) | |
| | | | | | | | | | | | | |
| 66 | 861 | 7.7 (5.9, 9.4) | 7.2 (5.3, 8.9) | 28 | 801 | 3.5 (2.2, 4.8) | 2.4 (1.1, 3.7) | 57 | 665 | 8.6 (6.4, 10.7) | 7.6 (5.4, 9.7) | |
| 94 | 1246 | 7.5 (6.1, 9.0) | 7 (5.5, 8.5) | 46 | 1177 | 3.9 (2.8, 5.0) | 2.8 (1.7, 4) | 76 | 1004 | 7.6 (5.9, 9.2) | 6.6 (4.9, 8.2) | |
| 60 | 846 | 7.1 (5.4, 8.8) | 6.6 (4.8, 8.3) | 27 | 809 | 3.3 (2.1, 4.6) | 2.2 (1, 3.5) | 47 | 686 | 6.9 (5, 8.7) | 5.9 (3.9, 7.7) | |
| 45 | 646 | 7.1 (5.1, 9.1) | 6.6 (4.5, 8.6) | 20 | 620 | 3.4 (2, 4.8) | 2.3 (0.9, 3.7) | 44 | 541 | 8.3 (6, 10.6) | 7.3 (5, 9.6) | |
| 38 | 860 | 4.4 (3.1, 5.8) | 3.8 (2.5, 5.2) | 13 | 828 | 1.6 (0.7, 2.4) | 0.5 (0, 1.3) | 34 | 719 | 4.7 (3.2, 6.3) | 3.6 (2.1, 5.3) | |
| | | | | | | | | | | | | |
| 165 | 1991 | 8.3 (7.1, 9.5) | 7.8 (6.6, 9) | 79 | 1900 | 4.2 (3.3, 5.1) | 3.1 (2.2, 4) | 134 | 1607 | 8.3 (7, 9.7) | 7.3 (6, 8.7) | |
| 134 | 2337 | 5.8 (4.8, 6.7) | 5.2 (4.2, 6.2) | 54 | 2212 | 2.5 (1.8, 3.1) | 1.4 (0.7, 2) | 120 | 1906 | 6.4 (5.3, 7.4) | 5.4 (4.2, 6.4) | |
| 4 | 131 | 3.1 (1.1, 6.1) | 2.5 (0.4, 5.5) | 1 | 123 | 0.8 (0, 2.4) | 0 (0, 1.3) | 4 | 102 | 3.9 (1.5, 7.7) | 2.8 (0, 6.7) | |
| 174 | 2953 | 5.9 (5.1, 6.8) | 5.3 (4.5, 6.3) | 81 | 2833 | 2.9 (2.3, 3.5) | 1.8 (1.2, 2.4) | 156 | 2410 | 6.5 (5.5, 7.5) | 5.5 (4.4, 6.5) | |
| 71 | 669 | 10.6 (8.3, 13.0) | 10.2 (7.8, 12.6) | 26 | 623 | 4.2 (2.6, 5.8) | 3.1 (1.5, 4.8) | 57 | 550 | 10.4 (7.8, 12.9) | 9.4 (6.8, 11.9) | |
| 31 | 369 | 8.4 (5.6, 11.2) | 7.9 (5, 10.8) | 13 | 342 | 3.8 (1.8, 5.8) | 2.7 (0.7, 4.8) | 25 | 285 | 8.8 (5.5, 12.1) | 7.8 (4.4, 11.1) | |
| 16 | 283 | 5.7 (3.0, 8.3) | 5.1 (2.4, 7.8) | 9 | 262 | 3.4 (1.2, 5.6) | 2.3 (0.1, 4.6) | 12 | 228 | 5.3 (2.4, 8.2) | 4.2 (1.3, 7.2) | |
| 0 | 18 | 0 (0, 0) | | 0 | 18 | 0 (0, 17.6) | 0 (0, 16.7) | 0 | 15 | | | |
| 11 | 167 | 6.6 (3.7, 11.4) | 6.1 (3.1, 11) | 5 | 157 | 3.2 (0.4, 5.9) | 2.1 (0, 4.9) | 8 | 127 | 6.3 (2.1, 10.5) | 5.3 (1, 9.5) | |
| | | | | | | | | | | | | |
| 5 | 52 | 9.6 (1.6, 21.0) | 9.1 (0.9, 20.9) | 3 | 47 | 6.4 (0, 13.4) | 5.4 (0, 12.4) | 3 | 43 | 7 (0, 14.6) | 6 (0, 13.7) | |
| 34 | 399 | 8.5 (5.8, 11.3) | 8 (5.2, 10.9) | 13 | 367 | 3.5 (1.7, 5.4) | 2.4 (0.6, 4.3) | 29 | 308 | 9.4 (6.2, 12.7) | 8.4 (5.2, 11.7) | |
| 72 | 1126 | 6.4 (5.0, 7.8) | 5.9 (4.4, 7.3) | 29 | 1053 | 2.8 (1.8, 3.8) | 1.7 (0.7, 2.7) | 62 | 871 | 7.1 (5.4, 8.8) | 6.1 (4.3, 7.8) | |
| 192 | 2882 | 6.7 (5.8, 7.6) | 6.2 (5.2, 7.1) | 89 | 2768 | 3.3 (2.6, 3.9) | 2.2 (1.5, 2.8) | 164 | 2393 | 6.9 (5.8, 7.9) | 5.9 (4.8, 6.9) | |
| 200 | 07.11 | | | 05 | 0.000 | 0.4.4.5.0.5 | | 150 | 221-5 | | | |
| 208 34 | 2741 535 | 7.6 (6.6, 8.6) 6.4 (4.3, 8.4) | 7.1 (6.1, 8.1) 5.9 (3.7, 7.9) | 95 15 | 2613 503 | 2.4 (1.5, 3.4) 1.9 (0.1, 3.7) | 1.3 (0.4, 2.3) 0.8 (0, 2.6) | 179 26 | 2216 429 | 8.1 (6.9, 9.2) 6.1 (3.8, 8.3) | 7.1 (5.9, 8.2) 5.1 (2.7, 7.3) | |
| | Number positive 303 66 94 60 45 38 165 134 4 174 71 31 16 0 11 5 34 72 192 208 | Number positive Total 303 4459 66 861 94 1246 60 846 45 646 38 860 165 1991 134 2337 4 131 174 2953 71 669 31 369 16 283 0 18 11 167 5 52 34 399 72 1126 192 2882 208 2741 | Period 1 or Period 2) NNumber positiveTotalCrude cumulative incidence (95% CI)30344596.8 (6.1, 7.6)668617.7 (5.9, 9.4)9412467.5 (6.1, 9.0)608467.1 (5.4, 8.8)456467.1 (5.1, 9.1)388604.4 (3.1, 5.8)16519918.3 (7.1, 9.5)13423375.8 (4.8, 6.7)41313.1 (1.1, 6.1)17429535.9 (5.1, 6.8)7166910.6 (8.3, 13.0)313698.4 (5.6, 11.2)162835.7 (3.0, 8.3)0180 (0, 0)111676.6 (3.7, 11.4)5529.6 (1.6, 21.0)343998.5 (5.8, 11.3)7211266.4 (5.0, 7.8)19228826.7 (5.8, 7.6)20827417.6 (6.6, 8.6) | Adjusted cumulative incidence (95% CI)Number positiveTotalCrude cumulative incidence (95% CI)Adjusted cumulative incidence (95% CI)30344596.8 (6.1, 7.6)6.3 (5.5, 7.1)668617.7 (5.9, 9.4)7.2 (5.3, 8.9)9412467.5 (6.1, 9.0)7 (5.5, 8.5)608467.1 (5.4, 8.8)6.6 (4.8, 8.3)456467.1 (5.1, 9.1)6.6 (4.5, 8.6)388604.4 (3.1, 5.8)3.8 (2.5, 5.2)16519918.3 (7.1, 9.5)7.8 (6.6, 9)13423375.8 (4.8, 6.7)5.2 (4.2, 6.2)41313.1 (1.1, 6.1)2.5 (0.4, 5.5)17429535.9 (5.1, 6.8)5.3 (4.5, 6.3)7166910.6 (8.3, 13.0)10.2 (7.8, 12.6)313698.4 (5.6, 11.2)7.9 (5, 10.8)162835.7 (3.0, 8.3)5.1 (2.4, 7.8)0180 (0, 0)11111676.6 (3.7, 11.4)6.1 (3.1, 11)5529.6 (1.6, 21.0)9.1 (0.9, 20.9)343998.5 (5.8, 11.3)8 (5.2, 10.9)7211266.4 (5.0, 7.8)5.9 (4.4, 7.3)19228826.7 (5.8, 7.6)6.2 (5.2, 7.1)20827417.6 (6.6, 8.6)7.1 (6.1, 8.1) | Period 1 or Period 2) N=4,459Number positiveCrude cumulative incidence (95% CI)Adjusted cumulative incidence (95% CI)Number positive30344596.8 (6.1,7.6)6.3 (5.5,7.1)134668617.7 (5.9, 9.4)7.2 (5.3, 8.9)289412467.5 (6.1, 9.0)7 (5.5, 8.5)46608467.1 (5.4, 9.0)7 (5.5, 8.5)46608467.1 (5.1, 9.1)6.6 (4.5, 8.6)20388604.4 (3.1, 5.8)3.8 (2.5, 5.2)1316519918.3 (7.1, 9.5)7.8 (6.6, 9)7913423375.8 (4.8, 6.7)5.2 (4.2, 6.2)5441313.1 (1.1, 6.1)2.5 (0.4, 5.5)117429535.9 (5.1, 6.8)5.3 (4.5, 6.3)817166910.6 (8.3, 13.0)10.2 (7.8, 12.6)26313698.4 (5.6, 11.2)7.9 (5, 10.8)13162835.7 (3.0, 8.3)5.1 (2.4, 7.8)90180 (0, 0)0111676.6 (3.7, 11.4)6.1 (3.1, 11)55529.6 (1.6, 21.0)9.1 (0.9, 20.9)3343998.5 (5.8, 11.3)8 (5.2, 10.9)137211266.4 (5.0, 7.8)5.9 (4.4, 7.3)2919228826.7 (5.8, 7.6)6.2 (5.2, 7.1)8920827417.6 (6.6, 8.6)7.1 (6.1, 8.1)95 | Image: Crude cumulative incidence cumulative incidence (95% C1)Adjusted cumulative incidence (95% C1)30344596.8 (6.1, 7.6)6.3 (5.5, 7.1)Number positive Total668617.7 (5.9, 9.4)7.2 (5.3, 8.9)288019412467.5 (6.1, 9.0)7 (5.5, 8.5)461177608467.1 (5.4, 8.8)6.6 (4.8, 8.3)27809456467.1 (5.1, 9.1)6.6 (4.5, 8.6)20620388604.4 (3.1, 5.8)3.8 (2.5, 5.2)1382816519918.3 (7.1, 9.5)7.8 (6.6, 9)79190013423375.8 (4.8, 6.7)5.2 (4.2, 6.2)54221241313.1 (1.1, 6.1)2.5 (0.4, 5.5)112317429535.9 (5.1, 6.8)5.3 (4.5, 6.3)8128337166910.6 (8.3, 13.0)10.2 (7.8, 12.6)26623313698.4 (5.6, 11.2)7.9 (5, 10.8)13342162835.7 (3.0, 8.3)5.1 (2.4, 7.8)92620180 (0.0)018111676.6 (3.7, 11.4)6.1 (3.1, 11)51575529.6 (1.6, 21.0)9.1 (0.9, 20.9)347343998.5 (5.8, 11.3)8 (5.2, 10.9)133677211266.4 (5.0, 7.8)5.9 (4.4, 7.3)29105319228826.7 (5.8, 7.6)6.2 (5.2, 7.1)892768< | (Period 1 or Period 2) N=4,459(N=4,235)Number positiveCrude cumulative incidence (95% CI)Adjusted cumulative incidence (95% CI)Crude cumulative incidence (95% CI)Crude cumulative incidence (95% CI)Crude cumulative incidence (95% CI)668617.7 (5.9, 9.4)7.2 (5.3, 8.9)28801 $3.5 (2.2, 4.8)$ 9412467.5 (6.1, 9.0)7 (5.5, 8.5)461177 $3.9 (2.8, 5.0)$ 608467.1 (5.4, 8.8)6.6 (4.8, 8.3)27809 $3.3 (2.1, 4.6)$ 456467.1 (5.1, 9.1)6.6 (4.5, 8.6)20620 $3.4 (2, 4.8)$ 388604.4 (3.1, 5.8)3.8 (2.5, 5.2)138281.6 (0.7, 2.4)16519918.3 (7.1, 9.5)7.8 (6.6, 9)7919004.2 (3.3, 5.1)13423375.8 (4.8, 6.7)5.2 (4.2, 6.2)5422122.5 (1.8, 3.1)141313.1 (1.1, 6.1)2.5 (0.4, 5.5)11230.8 (0, 2.4)17429535.9 (5.1, 6.8)5.3 (4.5, 6.3)8128332.9 (2.3, 3.5)7166910.6 (8.3, 13.0)10.2 (7.8, 12.6)266234.2 (2.6, 5.8)313698.4 (5.6, 11.2)7.9 (5, 10.8)133423.8 (1.8, 5.8)162835.7 (3.0, 8.3)5.1 (2.4, 7.8)92623.4 (1.2, 5.6)0180 (0, 0)0180 (0, 17.6)111676.6 (3.7, 11.4) <td< td=""><td>(Period 1 or Period 2) N=4,459 (N=4,235) Adjusted comulative positive Crude comulative incidence (95% CI) Adjusted comulative incidence (95% CI) Crude comulative incidence Adjusted comulative incidence 66 861 7.7 (5.9, 9.4) 7.2 (5.3, 8.9) 28 801 3.5 (2.2, 4.8) 2.4 (1.1, 3.7) 94 1246 7.5 (6.1, 9.0) 7 (5.5, 8.5) 46 1177 3.9 (2.8, 5.0) 2.8 (1.7, 4) 60 846 7.1 (5.4, 8.8) 6.6 (4.8, 8.3) 27 809 3.3 (2.1, 4.6) 2.2 (1, 3.5) 45 646 7.1 (5.1, 9.1) 6.6 (4.5, 8.6) 20 620 3.4 (2.4.8) 2.3 (0.9, 3.7) 38 860 4.4 (3.1, 5.8) 3.8 (2.5, 5.2) 13 828 1.6 (0.7, 2.4) 0.5 (0, 1.3) 165 1991 8.3 (7.1, 9.5) 7.8 (6.6.9) 79 1900 4.2 (3.3, 5.1) 3.1 (2.2, 4) 134 2337 5.8 (4.8, 6.7) 5.2 (4.2, 6.2) 54 2212 2.5 (1.8, 3.1) 1.4 (0.7, 2) 174 2953 5.9 (5.1, 6.8)</td><td>Image: Number Crude cumulative incidence (95% CI) Adjusted (95% CI) Number (95% CI) Crude cumulative incidence (95% CI) Number (95% CI) Nu</td><td>(N=4,235) Number Crude cumulative incidence (95% C1) Adjusted cumulative incidence (95% C1) Adjusted cumulative incidence (95% C1) Number Total Ossibility (95% C1) Number Number</br></td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td></td<> | (Period 1 or Period 2) N=4,459 (N=4,235) Adjusted comulative positive Crude comulative incidence (95% CI) Adjusted comulative incidence (95% CI) Crude comulative incidence Adjusted comulative incidence 66 861 7.7 (5.9, 9.4) 7.2 (5.3, 8.9) 28 801 3.5 (2.2, 4.8) 2.4 (1.1, 3.7) 94 1246 7.5 (6.1, 9.0) 7 (5.5, 8.5) 46 1177 3.9 (2.8, 5.0) 2.8 (1.7, 4) 60 846 7.1 (5.4, 8.8) 6.6 (4.8, 8.3) 27 809 3.3 (2.1, 4.6) 2.2 (1, 3.5) 45 646 7.1 (5.1, 9.1) 6.6 (4.5, 8.6) 20 620 3.4 (2.4.8) 2.3 (0.9, 3.7) 38 860 4.4 (3.1, 5.8) 3.8 (2.5, 5.2) 13 828 1.6 (0.7, 2.4) 0.5 (0, 1.3) 165 1991 8.3 (7.1, 9.5) 7.8 (6.6.9) 79 1900 4.2 (3.3, 5.1) 3.1 (2.2, 4) 134 2337 5.8 (4.8, 6.7) 5.2 (4.2, 6.2) 54 2212 2.5 (1.8, 3.1) 1.4 (0.7, 2) 174 2953 5.9 (5.1, 6.8) | Image: Number Crude cumulative incidence (95% CI) Adjusted (95% CI) Number (95% CI) Crude cumulative incidence (95% CI) Number (95% CI) Nu | (N=4,235) Number Crude cumulative incidence (95% C1) Adjusted | $ \begin{array}{ c c c c c c c c c c c c c c c c c c c$ | |

| Table S2. Crude and adjusted ³ | ** cumulative incidence estim | ates of SARS-CoV-2 | infection in CHASINO | G COVID Cohort St | udy partici | pants by time | e period of testing |
|---|-------------------------------|--------------------|----------------------|-------------------|-------------|---------------|---------------------|
| | | | | | | | |

| Homemaker | 14 | 240 | 6.2 (3.2, 9.3) | 5.7 (2.6, 8.8) | 6 | 225 | 3.5 (0.5, 6.4) | 2.4 (0, 5.4) | 11 | 194 | 6.2 (3, 9.5) | 5.2 (1.9, 8.5) |
|--------------------|-----|------|-----------------|-----------------|-----|------|----------------|----------------|-----|------|-----------------|-----------------|
| Student | 24 | 362 | 6.7 (4.1, 9.2) | 6.2 (3.5, 8.7) | 10 | 330 | 2 (0, 4.7) | 0.9 (0, 3.6) | 21 | 283 | 7.4 (4.4, 10.5) | 6.4 (3.3, 9.5) |
| Retired | 23 | 581 | 4.0 (2.4, 5.5) | 3.4 (1.7, 4.9) | 8 | 564 | 1.2 (0, 2.6) | 0.1 (0, 1.5) | 21 | 493 | 4.3 (2.5, 6) | 3.2 (1.4, 5) |
| Household income* | | | | | | | | | | | | |
| Less than \$35,000 | 82 | 1288 | 6.4 (5.1, 7.8) | 5.9 (4.5, 7.3) | 31 | 1213 | 2.3 (1.4, 3.1) | 1.2 (0.3, 2) | 71 | 1009 | 7.1 (5.5, 8.7) | 6.1 (4.4, 7.7) |
| \$35-49,999 | 40 | 487 | 8.2 (5.8, 10.6) | 7.7 (5.2, 10.2) | 17 | 457 | 3.7 (2, 5.4) | 2.6 (0.9, 4.3) | 34 | 402 | 8.5 (5.7, 11.2) | 7.5 (4.7, 10.2) |
| \$50-69,999 | 39 | 635 | 6.1 (4.3, 8.0) | 5.5 (3.7, 7.5) | 16 | 600 | 2.7 (1.4, 4) | 1.6 (0.3, 2.9) | 31 | 532 | 5.8 (3.8, 7.8) | 4.8 (2.7, 6.8) |
| \$70-99,999 | 57 | 734 | 7.8 (5.8, 9.7) | 7.3 (5.2, 9.2) | 26 | 706 | 3.7 (2.3, 5.1) | 2.6 (1.2, 4) | 49 | 624 | 7.9 (5.7, 9.9) | 6.9 (4.7, 8.9) |
| \$100,000+ | 85 | 1315 | 6.5 (5.1, 7.8) | 6 (4.5, 7.3) | 44 | 1259 | 3.5 (2.5, 4.5) | 2.4 (1.4, 3.4) | 73 | 1048 | 6 (5.4, 8.5) | 5 (4.3, 7.5) |
| Setting* | | | | | | | | | | | | |
| Urban | 136 | 1962 | 6.9 (5.8, 8.1) | 6.4 (5.2, 7.6) | 71 | 1873 | 3.9 (3, 4.8) | 2.8 (1.9, 3.7) | 111 | 1572 | 7.1 (5.8, 8.3) | 6.1 (4.8, 7.3) |
| Suburban | 78 | 1143 | 6.8 (5.4, 8.3) | 5.8 (4.3, 7.3) | 35 | 1092 | 3.2 (2.2, 4.3) | 2.1 (1.1, 3.2) | 68 | 928 | 7.3 (5.7, 9) | 6.3 (4.7, 8) |
| Rural | 89 | 1354 | 6.7 (5.3, 8.0) | 5.7 (4.2, 7) | 28 | 1270 | 2.3 (1.5, 3.1) | 1.2 (0.4, 2) | 79 | 1115 | 7.2 (5.7, 8.7) | 6.2 (4.7, 7.7) |
| Geographic region* | | | | | | | | | | | | |
| Northeast | 106 | 1294 | 8.3 (6.8, 9.8) | 7.8 (6.3, 9.4) | 72 | 1244 | 5.9 (4.6, 7.2) | 4.9 (3.5, 6.2) | 85 | 1023 | 8.4 (6.7, 10.1) | 7.4 (5.7, 9.1) |
| Midwest | 50 | 794 | 6.3 (4.6, 8.0) | 5.8 (4, 7.5) | 16 | 760 | 2.1 (1.1, 3.1) | 1 (0, 2) | 49 | 655 | 7.5 (5.5, 9.5) | 6.5 (4.4, 8.5) |
| South | 90 | 1269 | 7.2 (5.7, 8.6) | 6.6 (5.2, 8.1) | 31 | 1188 | 2.6 (1.8, 3.6) | 1.5 (0.7, 2.5) | 72 | 1037 | 6.9 (5.5, 8.6) | 5.9 (4.4, 7.6) |
| West | 57 | 1097 | 5.2 (3.9, 6.5) | 4.6 (3.3, 6) | 15 | 1038 | 1.5 (0.7, 2.2) | 0.4 (0, 1.1) | 52 | 896 | 5.8 (4.3, 7.3) | 4.8 (3.2, 6.3) |
| US Dep | 0 | 5 | 0 (0, 0) | | 0 | 5 | 0 (0, 0) | 0 (0, 0) | 0 | 4 | 0 (0, 0) | 0 (0, 0) |
| Healthcare worker* | | | | | | | | | | | | |
| No | 274 | 4042 | 6.8 (6.0, 7.6) | 6.3 (5.4, 7.1) | 124 | 3835 | 3 (2.2, 3.7) | 1.9 (1.1, 2.6) | 233 | 3283 | 7.1 (6.3, 8) | 6.1 (5.3, 7) |
| Yes | 29 | 417 | 7.0 (4.5, 9.4) | 6.5 (3.9, 8.9) | 10 | 400 | 2.4 (0.1, 4.7) | 1.3 (0, 3.6) | 25 | 332 | 7.5 (4.7, 10.4) | 6.5 (3.6, 9.4) |
| Essential worker | | | | | | | | | | | | |
| No | 257 | 3858 | 6.7 (5.9, 7.5) | 6.2 (5.3, 7) | 120 | 3662 | 3.3 (2.7, 3.9) | 1.9 (1.3, 2.5) | 218 | 3137 | 7 (6.1, 7.9) | 6 (5.1, 6.9) |
| Yes | 46 | 601 | 7.7 (5.5, 9.8) | 7.2 (4.9, 9.4) | 14 | 573 | 2.4 (1.2, 3.7) | 3.3 (1.8, 4.9) | 40 | 478 | 8.4 (5.9, 10.9) | 7.4 (4.9, 9.9) |
| High Risk group*** | | | | | | | | | | | | |
| No | 162 | 2074 | 7.8 (6.7, 9.0) | 7.3 (6.2, 8.5) | 79 | 1974 | 4.0 (3.1, 4.9) | 3 (2.1, 3.9) | 136 | 1669 | 8.2 (6.8, 9.5) | 6.9 (5.6, 8.3) |
| Yes | 141 | 2385 | 6.0 (5.0, 6.9) | 5.4 (4.4, 6.4) | 55 | 2261 | 2.5 (1.8, 3.1) | 1.4 (0.8, 2) | 122 | 1946 | 6.3 (5.2, 7.4) | 5.1 (4, 6.2) |
| | | | | | | | | | | | | |

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

**Adjusted for laboratory test performance

*** >60 years old, or reported co-morbidity, or current smoker.

Table S2.

Crude and adjusted** cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing.

| | | | with a serologic ollow-up) N=4,45 | | Partici | | erologic test in 4,235) | Period 1 | Participants with a serologic test in Period 2 (N=3,615) | | | | |
|---|--|--------------------|--|---|------------------|-----------------------|--|---|--|-----------------------|--|---|--|
| | Positive test (Period 1 and/or Period 2) | Total participants | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | Positive test | Total participants | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | Positive Test | Total Participants | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | |
| Total | 303 | 4459 | 6.8 (6.1, 7.6) | 6.3 (5.5, 7.1) | 134 | 4235 | 3.1 (2.7, 3.7) | 2.5 (2.1, 3.1) | 258 | 3615 | 7.2 (6.3, 8) | 6.7 (5.8, 7.5) | |
| Non-pharmaceutical interventions Did not use mask | 15 | 217 | 69(42111) | 6.4 (3.6, 10.7) | 3 | 200 | 1.5 (0.3, 4.3) | 0.8 (0, 3.7) | 14 | 274 | 5.1 (3.1, 8.4) | 4.5 (2.5, 7.9) | |
| | 27 | 299 | , | 8.6 (5.8, 12.4) | 9 | | , | 2.5 (0.7, 5.3) | 98 | | 7.2 (5.9, 8.7) | 6.7 (5.3, 8.2) | |
| Attended gatherings Attended Protests | | 299 | 9 (0.3, 12.8) | 8.0 (3.8, 12.4) | | 204 | 5.1 (1.4, 5.9) | 2.3 (0.7, 5.5) | | | , | | |
| | - | - | - | - | - | - | - | - | 11 | 169 | 6.5 (3.7, 11.3) | 6 (3.1, 10.9) | |
| Did not Self-Quarantine | 98 | 1554 | 6.3 (5.2, 7.6) | 5.8 (4.6, 7.1) | 28 | | 1.9 (1.2, 2.7) | | 211 | 3552 | 5.9 (5.2, 6.7) | 5.3 (4.6, 6.2) | |
| Decreased hand-washing | 6 | 96 | 6.2 (2.9, 12.9) | 5.7 (2.3, 12.5) | 2 | 91 | 2.1 (0.2, 7.7) | 1.4 (0, 7.2) | 24 | 389 | 6.2 (4.2, 9) | 5.7 (3.6, 8.5) | |
| Household factors | | | | | | | | | | | | | |
| Child in household | 77 | 1204 | 6.4 (5.1, 7.9) | 5.9 (4.5, 7.4) | 32 | 1126 | 2.8 (2, 4) | 2.2 (1.3, 3.4) | 62 | 961 | 6.4 (5.1, 8.2) | 5.9 (4.5, 7.7) | |
| Household crowding | | | | | | | | | | | | | |
| <4 persons in household | 222 | 3356 | 6.6 (5.8, 7.5) | 6.1 (5.2, 7) | 103 | 3207 | 3.2 (2.6, 3.8) | 2.6 (2, 3.2) | 188 | 2732 | 6.8 (5.9, 7.9) | 6.2 (5.3, 7.4) | |
| 4+ persons in single unit | 56 | 834 | 6.7 (5.2, 8.6) | 6.2 (4.6, 8.1) | 22 | 744 | 2.8 (1.8, 4.2) | 2.2 (1.1, 3.6) | 48 | 671 | 7.1 (5.4, 9.3) | 6.6 (4.8, 8.8) | |
| 4+ persons in multi unit | 23 | 249 | 9.2 (6.2, 13.5) | 8.7 (5.7, 13.2) | 9 | 236 | 3.8 (2, 7.1) | 3.2 (1.3, 6.6) | 20 | 199 | 10.1 (6.6, 15) | 9.7 (6.1, 14.7) | |
| History of COVID infection and testing | | | | | | | | | | | | | |
| Thought had COVID | 85 | 629 | 13.5 (11.1, 16.4) | 13.2 (10.7, 16.1) | 58 | 604 | 9.6 (7.5, 12.2) | 9.1 (7, 11.8) | 95 | 675 | 14.1 (11.6, 16.9) | 13.8 (11.2, 16.6) | |
| Known COVID exposure | - | - | - | - | - | - | - | - | 27 | 205 | , | 12.8 (8.7, 18.3) | |
| Sought a test | - | - | - | - | - | - | - | - | 169 | 1804 | 9.4 (8.1, 10.8) | 8.9 (7.6, 10.4) | |
| Self-reported positive diagnosis | - | - | - | - | - | - | - | - | 82 | 182 | 45.1 (38, 52.3) | 45.6 (38.3, 53) | |
| Self-reported hospitalization | - | - | - | - | - | - | - | - | 8 | 67 | 11.9 (6.2, 21.8) | 11.5 (5.7, 21.7) | |
| Knew someone who died | 33 | 435 | 7.6 (5.4, 10.5) | 7.1 (4.8, 10.1) | 17 | 416 | 4.1 (2.5, 6.4) | 3.5 (1.8, 5.9) | 84 | 1213 | 6.9 (5.6, 8.5) | 6.4 (5, 8) | |
| No Insurance | 55 | 663 | 8.3 (6.4, 10.6) | 7.8 (5.9, 10.2) | 23 | 616 | 3.7 (2.5, 5.5) | 3.1 (1.8, 4.9) | 80 | 1025 | 7.8 (6.3, 9.6) | 7.3 (5.8, 9.1) | |
| Comorbidities | | | | | | | | | | | | | |
| Asthma | 42 | 745 | 5.6 (4.2, 7.5) | 5 (3.6, 7) | 15 | 686 | 2.1 (1.2, 3.5) | 1.4 (0.5, 2.9) | 35 | 745 | 4.7 (3.4, 6.5) | 4.1 (2.8, 6) | |
| Heart attack | 4 | 53 | 7.6 (2.9, 17.8) | 7 (2.3, 17.6) | 1 | 50 | 1.9 (0.1, 10.4) | 1.2 (-0.7, 10) | 3 | 53 | 7.7 (2.6, 20.3) | 7.2 (2, 20.1) | |

Table S3. Crude and adjusted* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

| Immunosuppression | 3 | 135 | 2.2 (0.7, 6.3) | 1.6 (0, 5.8) | 2 | 129 | 1.5 (0.2, 5.4) | 0.8 (0, 4.8) | 3 | 135 | 2.8 (0.9, 7.8) | 2.1 (0.2, 7.3) |
|---------------------------------------|-----|------|------------------|-----------------|----|------|----------------|----------------|-----|------|------------------|----------------------------|
| Depression | 61 | 1056 | 5.7 (4.5, 7.3) | 5.1 (3.9, 6.8) | 16 | 995 | 1.6 (0.9, 2.5) | 0.9 (0.2, 1.8) | 55 | 1056 | 5.2 (4, 6.7) | 4.6 (3.4, 6.2) |
| Diabetes | 24 | 307 | 7.8 (5.3, 11.4) | 7.3 (4.7, 11) | 5 | 286 | 1.7 (0.5, 3.9) | 1 (-0.2, 3.3) | 24 | 307 | 7.8 (5.3, 11.4) | 7.3 (4.7, 11) |
| HIV | 20 | 214 | 9.3 (6.1, 13.9) | 8.8 (5.5, 13.6) | 7 | 192 | 3.5 (1.4, 7.1) | 2.9 (0.7, 6.6) | 17 | 214 | 7.9 (5.1, 12.4) | 7.4 (4.5, 12) |
| Other potential risk factors | | | | | | | | | | | | 5 |
| Alcohol use** | 26 | 253 | 10.3 (7.1, 14.6) | 9.9 (6.6, 14.3) | 9 | 233 | 3.7 (1.7, 6.9) | 3.1 (1, 6.4) | 26 | 340 | 7.6 (5.2, 10.9) | 7.1 (4.6, 10.5) |
| Substance use*** | - | - | - | - | - | - | - | - | 37 | 607 | 6.1 (4.4, 8.3) | 5.5 (3.8, 7.8) |
| Received Flu vaccine in 2019 | 136 | 1824 | 7.4 (6.3, 8.7) | 6.9 (5.8, 8.2) | 70 | 1751 | 4 (3.1, 5) | 3.4 (2.5, 4.4) | 114 | 1824 | 7.4 (6.1, 8.8) | 6.9 (5.5, 8.3) |
| PrEP for HIV prevention | - | - | - | - | - | - | - | - | 40 | 383 | 10.4 (7.7, 13.9) | 10 (7.2, 13.6) |
| Pets in home | - | - | - | - | - | - | - | - | 78 | 1382 | 5.6 (4.5, 7) | 5 (3.9, 6.5) |
| Public transportation | 25 | 276 | 9.1 (6.2, 13) | 8.6 (5.7, 12.6) | 11 | 258 | 4.2 (2.1, 7.5) | 3.6 (1.4, 7) | 87 | 1053 | 8.3 (6.7, 10.1) | 7.8 (6.2, 9.7) |
| History of air travel during pandemic | | - | | - | - | - | - | - | 56 | 701 | 7.9 (6.2, 10.2) | 7.4 (5.7, 9.8) ad |

Table S3.

Crude and adjusted* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

Table S4. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

| | No. of | | | | |
|---------------------------|--------------|------------|----------------------|-------------------|-------------------|
| | seronegative | No. of | Total | Incidence rate | |
| | | incident | PY*** of | per 100 PY*** | Rate Ratio |
| | participants | infections | | - | |
| | in Period 1 | infections | follow up | (95% CI) | (95% CI) |
| Total | 3280 | 145 | 1562.0 | 9.3 (7.9, 11.0) | |
| Total | 3280 | 145 | 1302.0 | 9.3 (7.9, 11.0) | - |
| Age group* | | | | | |
| 18-29 | 584 | 33 | 280.5 | 11.8 (8.3, 16.7) | 1.26 (0.79, 2) |
| 30-39 | 902 | 40 | 428.8 | 9.3 (6.8, 12.8) | -ref- |
| 40-49 | 626 | 31 | 294.7 | 10.5 (7.3, 15.1) | 1.13 (0.7, 1.8) |
| 50-59 | 494 | 20 | 237.1 | 8.4 (5.4, 13.2) | 0.9 (0.52, 1.54) |
| 60+ | 674 | 20 | 320.8 | 6.5 (4.2, 10.1) | 0.7 (0.41, 1.18) |
| Gender | 0/1 | 21 | 320.0 | 0.0 (1.2, 10.1) | 0.7 (0.11, 1.10) |
| Male | 1453 | 77 | 711.6 | 10.8 (8.6, 13.6) | 1.34 (0.96, 1.87) |
| Female | 1734 | 65 | 803.2 | 8.1 (6.3, 10.4) | -ref- |
| Non-binary/Trans | 93 | 3 | 43.1 | 7.0 (2.2, 22.0) | 0.86 (0.21, 2.43) |
| Race/Ethnicity* |)5 | 5 | ч <i>3</i> .1 | 7.0 (2.2, 22.0) | 0.00 (0.21, 2.43) |
| White | 2218 | 83 | 1085.4 | 7.6 (6.1, 9.5) | -ref- |
| Hispanic | 485 | 34 | 210.9 | 16.1 (11.4, 22.8) | 2.11 (1.4, 3.12) |
| Black | 249 | 15 | 109.5 | 13.7 (8.1, 23.1) | 1.79 (0.96, 3.13) |
| Asian | 199 | 13 7 | 94.6 | · · · · | |
| Asian Pacific Islander | 199 | 0 | 94.0 7.0 | 7.4 (3.5, 13.7) | 0.97 (0.41, 1.99) |
| | | | | - | 1 44 (0 57 2 1) |
| Other | 114 | 6 | 54.6 | 11.0 (4.8, 25.0) | 1.44 (0.57, 3.1) |
| Education | | | | | |
| Less than HS | 37 | 2 | 16.1 | 12.4 (3.0, 51.7) | 1.47 (0.24, 4.98) |
| HS grad | 268 | 13 | 115.2 | 11.3 (6.5, 19.7) | 1.34 (0.72, 2.33) |
| Some college | 774 | 39 | 353.0 | 11.0 (8.0, 15.2) | 1.31 (0.89, 1.89) |
| Collge grad | 2201 | 91 | 1077.6 | 8.4 (6.8, 10.4) | -ref- |
| Employment* | | | | | |
| Employed | 2005 | 96 | 963.3 | 10.0 (8.1, 12.2) | -ref- |
| Out of work | 387 | 17 | 179.5 | 9.5 (5.8, 15.4) | 0.95 (0.55, 1.56) |
| Homemaker | 176 | 6 | 77.2 | 7.8 (3.4, 17.6) | 0.78 (0.31, 1.67) |
| Student | 244 | 12 | 120.1 | 10.0 (5.6, 17.9) | 1 (0.53, 1.78) |
| Retired | 468 | 14 | 221.9 | 6.3 (3.7, 10.7) | 0.63 (0.35, 1.08) |
| Household income* | | | | | |
| Less than \$35,000 | 909 | 45 | 418.7 | 10.7 (8.0, 14.5) | 1.44 (0.93, 2.26) |
| \$35-49,999 | 361 | 19 | 168.8 | 11.3 (7.1, 17.9) | 1.51 (0.85, 2.63) |
| \$50-69,999 | 484 | 16 | 229.3 | 7.0 (4.2. 11.5) | 0.94 (0.51, 1.68) |
| \$70-99,999 | 574 | 30 | 275.7 | 10.9 (7.5. 15.7) | 1.46 (0.89, 2.38) |
| \$100,000+ | 952 | 35 | 469.5 | 7.5 (5.3, 10.4) | -ref- |
| Setting* | | | | | |
| Urban | 1426 | 54 | 693.6 | 7.9 (5.9, 10.2) | -ref- |
| Suburban | 846 | 36 | 404.3 | 8.9 (6.4, 12.4) | 1.14 (0.74, 1.74) |
| Rural | 1008 | 55 | 464.1 | 11.9 (9.0, 15.6) | 1.52 (1.04, 2.22) |
| Geographic region* | | | | | |
| Northeast | 910 | 30 | 447.6 | 6.7 (4.7, 9.6) | -ref- |
| | | | 1 | | |

| Midwest | 605 | 31 | 285.8 | 10.8 (7.6. 15.6) | 1.62 (0.98, 2.69) |
|--------------------|------|-----|--------|------------------|-------------------|
| South | 934 | 50 | 431.5 | 11.5 (8.7, 15.4) | 1.73 (1.1, 2.75) |
| West | 827 | 34 | 394.0 | 8.6 (6.1, 12.2) | 1.29 (0.79, 2.12) |
| US Dep | 4 | 0 | 2.0 | 0(,) | 0 (0, 11.75) |
| Healthcare worker* | | | | | |
| No | 2973 | 129 | 1416.1 | 9.1 (7.6, 10.9) | -ref- |
| Yes | 307 | 16 | 145.8 | 11.0 (6.6, 18.1) | 1.2 (0.69, 1.98) |
| Essential worker | | | | | |
| No | 2842 | 116 | 1356.8 | 8.5 (7.1, 10.3) | -ref- |
| Yes | 438 | 29 | 205.1 | 14.1 (9.7, 20.6) | 1.65 (1.09, 2.46) |
| High Risk group** | | | | | |
| No | 1506 | 72 | 722.5 | 10.0 (7.9, 12.6) | -ref- |
| Yes | 1774 | 73 | 839.5 | 8.7 (6.9, 11.0) | 0.87 (0.63, 1.21) |

*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

**>60 years old, or reported co-morbidity, or current smoker.

***PY = Person Years

Table S4.

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

| COVID Conort participants | No. of | | | | |
|---------------------------------------|---|----------------------------------|-----------------------------|--|------------------------|
| | seronegative participants in Period 1 | No. of incident infections | Total PY of follow up | Incidence rate per 100 PY (95% CI) | Rate Ratio (95% CI) |
| Total | 3280 | 145 | 1562 | 9.3 (7.9, 10.8) | |
| Household factors | | | | | |
| Household crowding | 785 | 35 | 259.38 | 13.5 (9.8, 18.1) | 1.61 (1.08, 2.32) |
| No household crowding | 2495 | 110 | 1302.62 | 8.4 (7.1, 10.1) | -ref- |
| Child in household | 932 | 40 | 421.65 | 9.5 (7, 12.6) | 1.03 (0.71, 1.47) |
| No child in household | 2348 | 105 | 1140.37 | 9.2 (7.6, 11) | -ref- |
| No Confirmed case in household member | 42 | 18 | 34.14 | 0.5 (0.32, 0.81) | -ref- |
| Confirmed case in household member | 82 | 25 | 14.73 | 1.7 (1.1, 2.5) | 3.2 (1.7, 6) |
| NA | 3156 | 102 | 1513.15 | 0.1 (0.05, 0.08) | |
| Social distancing | | | | | |
| Attended mass gathering(s) | 337 | 16 | 167.26 | 9.5 (5.9, 14.9) | 1.03 (0.6, 1.7) |
| Did not attend mass gathering(s) | 2943 | 129 | 1394.76 | 9.2 (7.8, 10.8) | -ref- |
| Indoor dining/bar | 1787 | 102 | 854.15 | 11.9 (9.9, 14.3) | 1.95 (1.38, 2.83) |
| No indoor dining/bar | 1489 | 43 | 707.86 | 6.1 (4.5, 8.1) | -ref- |
| Outdoor dining/bar | 1896 | 92 | 928.21 | 9.7 (7.8, 11.8) | 1.15 (0.85, 1.67) |
| No outdoor dining/bar | 1384 | 53 | 633.8 | 8.4 (6.4, 10.7) | -ref- |
| Visited place of worship | 341 | 26 | 158 | 16.4 (11.5, 21) | 1.95 (1.25, 2.93) |
| Did not visit place of worship | 2939 | 119 | 1404.02 | 8.4 (7.1, 10) | -ref- |

Table S5. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

| Visited public park/public pool Did not visit public park/pool | 2323 957 | 103 42 | 1131.22 430.8 | 9.1 (7.5, 10.9) 9.7 (7.3, 12.9) | 0.94 (0.66, 1.35) -ref- |
|---|-------------|-----------|------------------|------------------------------------|----------------------------|
| Mask indoor grocery shopping | | | | | |
| N/A (Did not go grocery shopping) | 161 | 8 | 77.77 | 10.3 (5.3, 19) | 1.17 (0.53, 2.27) |
| Always | 2959 | 125 | 1415.05 | 8.8 (7.4, 10.4) | -ref- |
| Sometimes | 128 | 12 | 54.73 | 21.9 (13, 21.5) | 2.49 (1.31, 4.36) |
| Never | 32 | 0 | 14.47 | 0 (0, 20.9) | 0 (0, 2.37) |
| Mask indoor visiting non-household members | | | | | |
| N/A (Did no visit non-household members indoors) | 666 | 27 | 688.8 | 3.9 (4.7, 5.6) | -ref- |
| Always | 1047 | 37 | 358.54 | 10.3 (7.5, 13.9) | 2.64 (1.6, 4.37) |
| Sometimes | 1081 | 51 | 369 | 13.8 (10.7, 17.7) | 3.54 (2.22, 5.69) |
| Never | 438 | 30 | 145.66 | 20.6 (14.8, 27.8) | 5.28 (3.11, 8.9) |
| Mask indoor at work | | | | | |
| N/A (Did not attend indoor workplace) | 1595 | 68 | 1005.17 | 6.7 (5.3, 8.4) | -ref- |
| Always | 1293 | 59 | 439.83 | 13.4 (10.5, 16.9) | 2 (1.4, 2.81) |
| Sometimes | 282 | 13 | 96.81 | 13.4 (8, 21.6) | 2 (1.06, 3.51) |
| Never | 61 | 5 | 20.19 | 24.7 (11.1, 46.5) | 3.69 (1.3, 8.46) |
| Mask indoor at salon/gym | | | | | |
| N/A (Did not attend salon/gym) | 2426 | 106 | 1290.06 | 8.2 (6.8, 9.8) | -ref- |
| Always | 699 | 32 | 237.52 | 13.5 (9.7, 18.4) | 1.65 (1.09, 2.41) |
| Sometimes | 31 | 3 | 9.91 | 30.3 (10.8, 60.7) | 3.7 (0.92, 10.26) |
| Never | 75 | 4 | 24.51 | 16.3 (6.5, 35.2) | 1.99 (0.62, 4.91) |
| Outdoor mask use | | | | | |
| Mask use outdoors | 1501 | 65 | 716.41 | 9.1 (7.2, 11.4) | 0.96 (0.69, 1.33) |
| No mask use outdoors | 1779 | 80 | 845.61 | 9.5 (7.6, 11.6) | -ref- |
| Gathered outside in groups >=10 | | | | | |
| No | 1897 | 66 | 898.78 | 7.3 (5.8, 9.2) | -ref- |
| Indoors only | 224 | 11 | 104.58 | 10.5 (6, 17.8) | 1.43 (0.72, 2.64) |
| Outdoors only | 661 | 35 | 322.47 | 10.9 (7.9, 14.7) | 1.48 (0.97, 2.22) |
| Indoors and outdoors | 498 | 33 | 236.19 | 14 (10.1, 19) | 1.9 (1.24, 2.88) |
| Movement during the pandemic | | | | | |
| Recent use of public transit | | | | | _ |
| Avoided or did not use | 2628 | 113 | 1251.33 | 9 (7.5, 10.7) | -ref- |
| Did not avoid | 652 | 32 | 310.69 | 10.3 (7.3, 14.2) | 1.14 (0.76, 1.67) |
| Recent Air travel (Aug-Nov) | | | | | |

| Yes | 410 | 29 | 199.11 | 14.6 (10.2, 20.1) | 1.72 (1.12, 2.55) |
|-----|------|-----|---------|-------------------|-------------------|
| No | 2870 | 116 | 1362.91 | 8.5 (7.1, 10.1) | -ref- |

Table S5.

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

| | All seropositi persons | | | Observed roconverters egative in Period l seropostive in Period 2) | (sero first | alent cases positive on t antibody test) | Seroreversions (seropositive in Period 1, seronegative in Period 2) | |
|---|------------------------------|------|----------|--|----------------|---|--|------|
| Total | N 202 | % | N 145 | % | N 120 | % 45.5 | N 20.0 | % |
| Symptoms and clinical outcomes | 303 | 100 | 145 | 47.9 | 138 | 45.5 | 20.0 | 6.6 |
| Aware of past SARS-CoV-2 infection (footnote) | 121 | 39.9 | 35 | 24.1 | 74 | 53.6 | 12.0 | 60.0 |
| PCR confirmed diagnosis | 89 | 29.4 | 42 | 29.0 | 41 | 29.7 | 6.0 | 30.0 |
| Asymptomatic (footnote details) | 83 | 27.4 | 37 | 25.5 | 39 | 28.3 | 0.0 7.0 | 35.0 |
| Mild (symptomatic, but didn't seek care) | 190 | 62.7 | 87 | 60.0 | 87 | 63.0 | 16.0 | 80.0 |
| History of COVID like illness at baseline* | 121 | 39.9 | 51 | 35.2 | 62 | 44.9 | 8.0 | 40.0 |
| Ever had COVID like illness* | 209 | 69.0 | 105 | 72.4 | 93 | 67.4 | 11.0 | 55.0 |
| Nasal discharge, congestion or sneezing | 225 | 74.3 | 105 | 73.8 | 103 | 74.6 | 15.0 | 75.0 |
| Cough/Cough up phlegm | 158 | 52.2 | 77 | 53.1 | 70 | 50.7 | 11.0 | 55.0 |
| Cough up blood | 2 | 0.7 | 1 | 0.7 | 0 | 0.0 | 1.0 | 5.0 |
| Sore throat | 140 | 46.2 | 71 | 49.0 | 61 | 44.2 | 8.0 | 40.0 |
| Itchy eye or eye pain | 114 | 37.6 | 58 | 40.0 | 48 | 34.8 | 8.0 | 40.0 |
| Shortness of breath or chest pain | 91 | 30.0 | 37 | 25.5 | 49 | 35.5 | 5.0 | 25.0 |
| Stomachache, diarrhea, nausea or vomiting | 142 | 46.9 | 64 | 44.1 | 69 | 50.0 | 9.0 | 45.0 |
| Rash | 25 | 8.3 | 12 | 8.3 | 10 | 7.3 | 3.0 | 15.0 |
| Loss of smell | 61 | 20.1 | 30 | 20.7 | 28 | 20.3 | 3.0 | 15.0 |
| Headache | 202 | 66.7 | 93 | 64.1 | 97 | 70.3 | 12.0 | 60.0 |
| Fever, chills or repeated chills | 120 | 39.6 | 50 | 34.5 | 61 | 44.2 | 9.0 | 45.0 |
| Myalgia | 106 | 35.0 | 58 | 40.0 | 45 | 32.6 | 3.0 | 15.0 |
| Ever hospitalized | 10 | 3.3 | 3 | 2.1 | 7 | 5.1 | 0.0 | 0.0 |
| Public health outcomes and testing history | | | | | | | | |
| Ever tested for COVID | 195 | 64.4 | 92 | 63.5 | 91 | 65.9 | 12 | 60.0 |
| Postive SARS-CoV-2 PCR test | 97 | 32.0 | 43 | 29.7 | 48 | 34.8 | 6.0 | 30.0 |
| Isolated from people outside household | 93 | 30.7 | 42 | 29.0 | 45 | 32.6 | 6 | 30.0 |
| Isolated from people within household | 41 | 13.5 | 23 | 15.9 | 16 | 11.6 | 2 | 10.0 |
| Quarantined after contact with COVID | 30 | 9.9 | 23 | 15.9 | 6 | 4.3 | 1 | 5.0 |
| Asked about contacts after COVID diagnosis | 54 | 17.8 | 29 | 20.0 | 24 | 17.4 | 1 | 5.0 |
| Told about contacts with COVID case | 23 | 7.6 | 10 | 6.9 | 8 | 5.8 | 5 | 25.0 |
| Encouraged to get tested because of contact with COVID case | 12 | 4.0 | 6 | 4.1 | 2 | 1.4 | 4 | 20.0 |
| Told to stay home for a period of time | 10 | 3.3 | 4 | 2.8 | 4 | 2.9 | 2 | 10.0 |

*based on CTSE case definition

Table S6.

Characteristics of persons with seroprevalent and seroincident SARS-CoV-2

| | | Specimens positive by Total Ab in Period 1 or Period 2 | | Individuals positive by Total Ab in Period 1 | | Individuals positive by Total Ab in Period 2 | | Seroconverters (seropositive by Total AB in Period 1, seronegative by Total AB in Period 2) | | Seroreverters (seropositive by Total AB in Period 1, seronegative by Total Ab in Period 2) | |
|------------------------------|-----|--|-----|---|-----|---|-----|---|---------|--|--|
| Total | 392 | 100% | 134 | 100% | 258 | 100% | 145 | 100% | N 20 | % 100.0 | |
| Spike IgG result | 572 | 10070 | 134 | 10070 | 250 | 10070 | 175 | 10070 | 20 | 100.0 | |
| Equivocal | 28 | 7.1% | 8 | 6.0% | 20 | 7.8% | 6 | 4.1% | 2 | 10.0% | |
| Non-Reactive | 132 | 33.7% | 31 | 23.1% | 101 | 39.1% | 64 | 44.1% | 13 | 65.0% | |
| Quantity Not Sufficient | 31 | 7.9% | 7 | 5.2% | 24 | 9.3% | 14 | 9.7% | 0 | 0.0% | |
| Reactive | 201 | 51.3% | 88 | 65.7% | 113 | 43.8% | 61 | 42.1% | 5 | 25.0% | |
| % reactive (excluding QNS**) | | 63.4% | | 75.6% | | 56.8% | | 51.1% | | 35.0% | |

Table S7. Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein

*392 seropositive samples from 303 seropositive participants

**Quantity not sufficient for serologic testing

Table S7.

Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein